

POSITION PAPER

International consensus on (ICON) pediatric asthma

N. G. Papadopoulos¹, H. Arakawa², K.-H. Carlsen³, A. Custovic⁴, J. Gern⁵, R. Lemanske⁶, P. Le Souef⁷, M. Mäkelä⁸, G. Roberts⁹, G. Wong¹⁰, H. Zar¹¹, C. A. Akdis¹², L. B. Bacharier¹³, E. Baraldi¹⁴, H. P. van Bever¹⁵, J. de Blic¹⁶, A. Boner¹⁷, W. Burks¹⁸, T. B. Casale¹⁹, J. A. Castro-Rodriguez²⁰, Y. Z. Chen²¹, Y. M. El-Gamal²², M. L. Everard²³, T. Frischer²⁴, M. Geller²⁵, J. Gereda²⁶, D. Y. Goh²⁷, T. W. Guilbert²⁸, G. Hedlin²⁹, P. W. Heymann³⁰, S. J. Hong³¹, E. M. Hossny³², J. L. Huang³³, D. J. Jackson³⁴, J. C. de Jongste³⁵, O. Kalayci³⁶, N. Ait-Khaled³⁷, S. Kling³⁸, P. Kuna³⁹, S. Lau⁴⁰, D. K. Ledford⁴¹, S. I. Lee⁴², A. H. Liu⁴³, R. F. Lockey⁴⁴, K. Lødrup-Carlsen⁴⁵, J. Lötvall⁴⁶, A. Morikawa⁴⁷, A. Nieto⁴⁸, H. Paramesh⁴⁹, R. Pawankar⁵⁰, P. Pohunek⁵¹, J. Pongracic⁵², D. Price⁵³, C. Robertson⁵⁴, N. Rosario⁵⁵, L. J. Rossenwasser⁵⁶, P. D. Sly⁵⁷, R. Stein⁵⁸, S. Stick⁵⁹, S. Szefer⁶⁰, L. M. Taussig⁶¹, E. Valovirta⁶², P. Vichyanond⁶³, D. Wallace⁶⁴, E. Weinberg⁶⁵, G. Wennergren⁶⁶, J. Wildhaber⁶⁷ & R. S. Zeiger⁶⁸

¹Department of Allergy, 2nd Pediatric Clinic, University of Athens, Athens, Greece; ²Department of Pediatrics, Graduate School of Medicine, Gunma University, Gunma, Japan; ³Department of Pediatrics, Oslo University Hospital, Oslo, Norway; ⁴Respiratory Research Group, University Hospital of South Manchester NHS Foundation Trust, Manchester, UK; ⁵Department of Pediatrics, University of Wisconsin Medical School, Madison, WI, USA; ⁶Division of Pediatric Allergy, Immunology, and Rheumatology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA; ⁷School of Pediatrics and Child Health, University of Western Australia, Princess Margaret Hospital, Perth, WA, Australia; ⁸Pediatric Unit, Helsinki University Central Hospital, Helsinki, Finland; ⁹Academic Unit of Human Development and Health, Southampton University Hospital NHS Trust, Southampton, UK; ¹⁰Department of Pediatrics, Chinese University of Hong Kong, Sha Tin, Hong Kong, SAR, China; ¹¹Department of Pediatrics and Child Health, Red Cross War Memorial Children's Hospital, University of Cape Town, Cape Town, South Africa; ¹²Swiss Institute of Allergy and Asthma Research (SIAF), Davos, Switzerland; ¹³Division of Pediatric Allergy, Immunology and Pulmonary Medicine, Department of Pediatrics, Washington University School of Medicine and St Louis Children's Hospital, St Louis, MO, USA; ¹⁴Department of Pediatrics, Unit of Allergy and Respiratory Medicine, University of Padova, Padova, Italy; ¹⁵Department of Paediatrics, Children's Medical Institute, National University Hospital, National University Health System, Singapore, Singapore; ¹⁶Université Paris Descartes, Assistance Publique des Hôpitaux de Paris, Service de Pneumologie et Allergologie Pédiatriques, Paris, France; ¹⁷Department of Paediatrics, University of Verona, Verona, Italy; ¹⁸Division of Allergy and Immunology, Department of Pediatrics, Duke University Medical Center, Durham, NC, USA; ¹⁹Division of Allergy and Immunology, Department of Medicine, Creighton University, Omaha, NE, USA; ²⁰School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile; ²¹Capital Institute of Pediatrics, Beijing, China; ²²Pediatric Allergy and Immunology Unit, Ain Shams University, Cairo, Egypt; ²³Department of Respiratory Medicine, Sheffield Children's Hospital, Western Bank, Sheffield, UK; ²⁴University Children's Hospital Vienna, Vienna, Austria; ²⁵Geller Allergy and Immunology Clinic, Rio de Janeiro, Brazil; ²⁶Department of Allergy and Immunology, Clinica Ricardo Palma, Lima, Peru; ²⁷Department of Paediatrics, National University Hospital, Singapore, Singapore; ²⁸School of Medicine and Public Health, University of Wisconsin, Madison, WI, USA; ²⁹Astrid Lindgren Children's Hospital, Karolinska University Hospital, Stockholm, Sweden; ³⁰Asthma and Allergic Diseases Center, University of Virginia, Charlottesville, VA, USA; ³¹Department of Pediatrics, Childhood Asthma Atopy Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea; ³²Pediatric Allergy and Immunology Unit, Children's Hospital, Ain Shams University, Cairo, Egypt; ³³Division of Allergy, Asthma and Rheumatology, Department of Pediatrics, Chang Gung Children's Hospital, Taoyuan, Taiwan; ³⁴Department of Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA; ³⁵Department of Pediatrics, Erasmus University Medical Center, Sophia Children's Hospital, Rotterdam, The Netherlands; ³⁶Pediatric Allergy and Asthma Unit, Ihsan Dogramaci Children's Hospital, Hacettepe University School of Medicine, Ankara, Turkey; ³⁷International Union Against Tuberculosis and Lung Disease (The Union), Cheraga, Algiers, Algeria; ³⁸Department of Paediatrics & Child Health, Tygerberg Children's Hospital, Stellenbosch University, Cape Town, South Africa; ³⁹Second Department of Medicine, Barlicki University Hospital, Medical University of Lodz, Lodz, Poland; ⁴⁰Department of Pediatric Pneumology and Immunology, Charité Medical University Berlin, Berlin, Germany; ⁴¹Division of Allergy/Immunology, University of South Florida, Tampa, FL, USA; ⁴²Department of Pediatrics, Environmental Health Center, Samsung Medical Center, School of Medicine, Sungkyunkwan University, Seoul, Korea; ⁴³National Jewish Health and University of Colorado Denver School of Medicine, Denver, CO, USA; ⁴⁴Division of Allergy/Immunology, University of South Florida, Tampa, FL, USA; ⁴⁵Woman and Child Division, Department of Paediatrics, Ullevål University Hospital, Oslo, Norway; ⁴⁶Krefting Research Centre, University of Gothenburg, Gothenburg, Sweden; ⁴⁷Kita Kanto Allergy Institute, Gunma University, Maebashi, Gunma, Japan; ⁴⁸Pediatric Allergy Unit, Children's Hospital La Fe, Valencia, Spain; ⁴⁹Lakeside Medical Center and Hospital, Bangalore, India; ⁵⁰Division of Allergy & Immunology, Department of Pediatrics, Nippon Medical School, Tokyo, Japan; ⁵¹Department of Pediatrics, University Hospital Motol, Charles University, Prague, Czech Republic; ⁵²Division of Allergy & Immunology, Children's Memorial Hospital, Chicago, IL, USA; ⁵³Primary Care Respiratory Society UK, University of Aberdeen, Aberdeen, UK; ⁵⁴The Royal Children's Hospital Melbourne, Melbourne, Vic., Australia; ⁵⁵Division of Pediatric Allergy, Hospital de Clinicas UFPR, Parana, Brazil; ⁵⁶Children's Mercy Hospital, Kansas City, MO, USA; ⁵⁷Queensland Children's Medical Research Institute, The University of Queensland, Brisbane, Qld, Australia; ⁵⁸Pediatric Pulmonary Service, Hospital São Lucas, Pontificia Universidade Católica RGS, Porto Alegre, Brazil; ⁵⁹Department of Respiratory Medicine, Princess Margaret Hospital for Children, Perth, WA, Australia; ⁶⁰Department of Pediatrics, National Jewish Health, Denver, CO, USA; ⁶¹Office of the Provost, University of Denver, Denver, CO, USA; ⁶²Terveystalo Turku, Allergy Clinic, University of Turku, Turku, Finland; ⁶³International Affairs and Centers for Excellence, Faculty of Medicine, Siriraj Hospital, Bangkok, Thailand; ⁶⁴Nova Southeastern University, Ft Lauderdale, FL, USA; ⁶⁵Allergy Unit, Red Cross Children's Hospital, University of Cape Town, Cape Town, South Africa; ⁶⁶Department of Pediatrics, University of Gothenburg, Gothenburg, Sweden; ⁶⁷Department of Respiratory Medicine, University Children's Hospital, Zurich, Switzerland; ⁶⁸Department of Allergy, Kaiser Permanente Southern California, San Diego, CA, USA

To cite this article: Papadopoulos NG, Arakawa H, Carlsen K-H, Custovic A, Gern J, Lemanske R, Le Souef P, Mäkelä M, Roberts G, Wong G, Zar H, Akdis CA, Bacharier LB, Baraldi E, van Bever HP, de Blic J, Boner A, Burks W, Casale TB, Castro-Rodriguez JA, Chen YZ, El-Gamal YM, Everard ML, Frischer T, Geller M, Gereda J, Goh DY, Guilbert TW, Hedlin G, Heymann PW, Hong SJ, Hossny EM, Huang JL, Jackson DJ, de Jongste JC, Kalayci O, Ait-Khaled N, Kling S, Kuna P, Lau S, Ledford DK, Lee SI, Liu AH, Lockey RF, Lødrup-Carlsen K, Lötvalld J, Morikawa A, Nieto A, Paramesh H, Pawankar R, Pohunek P, Pongracic J, Price D, Robertson C, Rosario N, Rossenwasser LJ, Sly PD, Stein R, Stick S, Szeffler S, Taussig LM, Valovirta E, Vichyanond P, Wallace D, Weinberg E, Wennergren G, Wildhaber J, Zeiger RS. International consensus on (icon) pediatric asthma. *Allergy* 2012; **67**: 976–997.

Keywords

asthma; children; consensus; guidelines; wheeze.

Correspondence

Nikolaos G. Papadopoulos, Department of Allergy, 2nd Pediatric Clinic, University of Athens, 41, Fidippidou street, Athens 115 27, Greece.

Tel.: +30 (210) 7776964

Fax: +30 (210) 7777693

E-mail: ngp@allergy.gr

Accepted for publication 30 May 2012

DOI:10.1111/j.1398-9995.2012.02865.x

Edited by: Michael Wechsler

Abstract

Asthma is the most common chronic lower respiratory disease in childhood throughout the world. Several guidelines and/or consensus documents are available to support medical decisions on pediatric asthma. Although there is no doubt that the use of common systematic approaches for management can considerably improve outcomes, dissemination and implementation of these are still major challenges. Consequently, the International Collaboration in Asthma, Allergy and Immunology (iCAALL), recently formed by the EAACI, AAAAI, ACAAI, and WAO, has decided to propose an International Consensus on (ICON) Pediatric Asthma. The purpose of this document is to highlight the key messages that are common to many of the existing guidelines, while critically reviewing and commenting on any differences, thus providing a concise reference. The principles of pediatric asthma management are generally accepted. Overall, the treatment goal is disease control. To achieve this, patients and their parents should be educated to optimally manage the disease, in collaboration with health-care professionals. Identification and avoidance of triggers is also of significant importance. Assessment and monitoring should be performed regularly to re-evaluate and fine-tune treatment. Pharmacotherapy is the cornerstone of treatment. The optimal use of medication can, in most cases, help patients control symptoms and reduce the risk for future morbidity. The management of exacerbations is a major consideration, independent of chronic treatment. There is a trend toward considering phenotype-specific treatment choices; however, this goal has not yet been achieved.

Asthma is the most common chronic lower respiratory disease in childhood throughout the world. Asthma most often starts early in life and has variable courses and unstable phenotypes which may progress or remit over time. Wheeze in preschool children may result from a number of different conditions; around half of preschool wheezers become asymptomatic by school age irrespective of treatment. However, asthma symptoms may persist, often for life, especially in atopic and more severe cases. The impact of asthma on the quality of life of patients, as well as its cost, is very high. Therefore, appropriate asthma management may have a major impact on the quality of life of patients and their families, as well as on public health outcomes (1). Asthma in childhood is strongly associated with allergy, especially in developed countries. Common exposures such as tobacco smoke, air pollution, and respiratory infections may trigger symptoms and contribute to the morbidity and occasional mortality. Currently, primary prevention is not possible. However, in established disease, control can be achieved and maintained with appropriate treatment, education, and monitoring in most children.

In children, asthma often presents with additional challenges not all of which are seen in adults, because of the maturing of the respiratory and immune systems, natural history, scarcity of good evidence, difficulty in establishing the diagnosis and delivering medications, and a diverse and frequently unpredictable response to treatment.

It is therefore not surprising that several guidelines and/or consensus documents are available to support medical decisions on pediatric asthma. These vary in scope and methodology, local, regional, or international focus, or their exclusivity to pediatric asthma. Although there is no doubt that the use of common systematic approaches for management, such as guidelines or national programs, can considerably improve outcomes, dissemination and implementation of these recommendations are still major challenges.

For these reasons, the International Collaboration in Asthma, Allergy and Immunology (iCAALL) (2), formed in 2012 by the EAACI, AAAAI, ACAAI, and WAO, helped organize an international writing group to address this unmet need with an International Consensus on (ICON) Pediatric Asthma. The purpose of this document is to highlight the

key messages that are common to many of the existing guidelines, while critically reviewing and commenting on any differences, thus providing a concise reference.

Methodology

A working committee was formed and approved by the Steering Committee of iCAALL and the participating organizations (authors 1–11). The criteria used for the formation of the committee were international representation, relevance to the field, and previous participation in pediatric asthma guidelines. The members of the committee proposed relevant documents to be appraised. These were the Australian Asthma Management Handbook, 2006 (AAMH) (3), the Global Strategy for Asthma Management and Prevention, published by GINA and updated in 2011 (GINA) (4), Global Strategy for the Diagnosis and Management of Asthma in Children 5 Years and Younger, 2009 (GINA < 5) (5), the Japanese Guideline for Childhood Asthma, 2008 (JGCA) (6), the National Heart and Blood Institute, National Asthma Education and Prevention Program, Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma, 2007 (NAEPP) (7), the Diagnosis and treatment of Asthma in Childhood: a PRACTALL Consensus Report, 2008 (PRACTALL) (8), and the British Guideline on the Management of Asthma, Revised 2011 (SIGN) (9). Each member undertook responsibility for preparing tables and relevant commentaries comparing the included documents in a specific domain. These were subsequently compiled into a first draft which was circulated among the authors for comments and corrections. The revised document was then circulated among an independent reviewing group (authors 12–68), the comments of which were taken into account in the final draft, which was approved by the governing bodies of the participating organizations and submitted for publication. Recommendations were extrapolated from the reference documents and presented using Evidence levels (A–D) (10).

Definition and classifications of pediatric asthma

Definition

The complexity and diversity of asthma in both children and adults are indisputable and what is 'true' asthma is frequently argued, especially in childhood. Nevertheless, no guideline proposes a differentiation between pediatric and adult asthma in regard to the definition.

All current definitions are descriptive, including symptoms and their patterns, as well as underlying mechanisms, at different levels of detail. With only minor deviations in term usage, asthma is understood as a chronic disorder, presenting with recurrent episodes of wheeze, cough, difficulty in breathing, and chest tightness, usually associated with variable airflow obstruction and bronchial (airway) hyperresponsiveness (BHR or AHR).

Chronic inflammation is recognized as the central pathology. In contrast, airway remodeling is only mentioned in the definition of the JGCA. The causal link(s) between chronic inflammation, BHR, and symptoms are poorly defined; some

definitions suggest that inflammation causes symptoms and BHR, others that BHR causes the symptoms, and yet others that this relationship is unclear.

Definitions often include more details, such as specific cell types (e.g. mast cells, eosinophils, etc.), timing of symptoms (particularly at night or early morning), reversibility (often), or triggers (viral infection, exercise, and allergen exposure). The relative importance of each of these additional elements can be argued; nevertheless, they are neither necessary for nor exclusive to asthma and therefore do not add appreciably to the sensitivity or specificity of the previously mentioned, generally accepted elements.

Taking the above into account, a working definition, representing a synopsis from all guidelines, is shown in Box 1.

Box 1

Asthma definition

Asthma is a chronic inflammatory disorder associated with variable airflow obstruction and bronchial hyperresponsiveness. It presents with recurrent episodes of wheeze, cough, shortness of breath, and chest tightness.

Classifications

To address diversity and guide management, several factors have been used to classify pediatric asthma (Fig. 1).

Age is an important classification factor, relevant to diagnosis and treatment. There is general consensus that milestone ages are around 5 and 12 years, and important clinical and epidemiological characteristics appear to change around those ages. In some documents, 'infantile' asthma (<2 or 3 years) is further distinguished. Special characteristics of adolescence are emphasized in most documents (Fig. 1A).

There is slightly less consistency when it comes to severity and persistence, which have been extensively used in the past to classify asthma. With respect to persistence, asthma is usually classified as intermittent or persistent; in addition, infrequent and frequent intermittent classes are proposed by the AAMH. With respect to severity, persistent asthma is usually classified as mild, moderate, and severe. However, in PRACTALL and SIGN, only severe asthma is mentioned, while in the JGCA, a 'most severe' class is proposed. Classifications of severity/persistence are challenging as they require differentiation between the inherent severity of the disease, resistance to treatment, and other factors, such as adherence to treatment. Hence, these classifications are currently recommended only for initial assessment of the disease severity and are being replaced by the concept of 'control', which is more clinically useful.

Control is generally accepted as a dynamic classification factor, critical to guiding treatment. Control categories are quite relevant in clinical practice. Slightly different terms are used for the levels of asthma control, which are generally three (controlled, partly controlled, and uncontrolled). In some cases, 'complete' control is described, as a state with no disease activity (Table 1).




Figure 1 Pediatric asthma is a diverse condition and several factors can be used for its classification. Important changes in clinical presentation take place in relation to age (upper left). Although limits are arbitrary and may differ between individuals, infancy, pre-school age, school age and adolescence are generally considered as milestones. Phenotypes (upper right) may result from different underlying pathophysiological (endotypes), however, there is con-

siderable overlap and possible changes over time. Severity (lower left) can range from very mild to life-threatening; although not necessarily discrete, a stepwise approach has been used to characterize severity and inform treatment initiation. More recently, the level of control (lower right) of both current symptoms and risk of future morbidity is preferred as a measure, towards which asthma management is evaluated.

In assessing severity and control, a distinction between current impairment and future risk is proposed by NAEPP and GINA. Although not stated in the other documents, these two elements are clearly distinguishable and may differentially respond to treatment; therefore, they should be considered independently.

Subgrouping into phenotypes is frequently mentioned: GINA and GINA <5 refer to different phenotypic classification systems, commenting that their clinical usefulness remains a subject of investigation. NAEPP suggests that evidence is emerging for phenotypic differences that may influence treatment choices, but does not propose a specific classification system. PRACTALL proposes a phenotypic classification according to apparent trigger (virus-induced, exercise-induced, allergen-induced, and unresolved), suggesting that these should be taken into account for treatment selection. The above variation may reflect the rapidly developing evidence with respect to different subgroups of pediatric asthma. For many patients, several apparent triggers may be identified, also varying over time, highlighting the difficulty in providing a simple phenotypic classification system. Future phenotypic classifications should demonstrate important advantages in management. Notably, most documents give special consideration to 'exercise-induced asthma' and 'severe asthma'.

Research Recommendations

- Asthma phenotypes in childhood should be further characterized in detail and defined, using epidemiological, statistical, and biological criteria
- Geopolitical particularities (e.g. low-income countries, climate zones) to be taken into account
- The existence of distinct pathophysiological mechanisms underlying a clinical presentation (endotypes) should be evaluated in children
- The clinical value of phenotype/endotype classifications, including differential response to treatment and/or natural history, needs to be demonstrated
- Phenotype-specific biomarkers will be useful in practice
- The time points when wheeze/asthma changes character may be identified with more precision

Guideline Update Recommendations

- Remodeling can be considered in future definitions of asthma
- Current impairment and future risk should be considered in future guidelines

Table 1 Asthma control

| Domain | Component | Level of control | | | |
|------------|--|------------------|-----------|----------|------------|
| | | Complete | Good | Partial | None |
| Impairment | Symptoms – daytime | None | ≤ 2/week | >2/week | Continuous |
| | Symptoms – nighttime/awakenings | None | ≤ 1/month | >1/month | Weekly |
| | Need for rescue medication | None | ≤ 2/week | >2/week | Daily |
| | Limitation of activities | None | None | Some | Extreme |
| | Lung function – FEV1, PEF (predicted or personal best) | >80% | ≥ 80% | 60–80% | <60% |
| Risk | Exacerbations (per year) | 0 | 1 | 2 | >2 |
| | Medication side effects | None | | Variable | |

Components of asthma control include current impairment (symptoms, need for rescue medication, limitation of activities, lung function in children >5 years) and future risk (exacerbations, medication side effects). Levels of control are indicative; the most severe impairment or risk defines the level.

- Phenotype/endotype differences in diagnosis and management should be addressed in more detail

Pathogenesis and pathophysiology

There is general agreement that asthma is a disease of chronic inflammation, airway hyperresponsiveness, and chronic structural changes known as airway remodeling (Fig. 2). Some of the guidelines provide extensive discussion of these topics, while others focus mostly on diagnosis and treatment and mention these concepts in introductory remarks or as part of an asthma definition.

Asthma can begin at any age but most often has its roots in early childhood (11). The prevalence of asthma has increased in many countries (12), although in some cases it may have leveled off (12, 13). As asthma inception depends on both genetics (14, 15) and the environment (16), modifiable environmental factors have been sought in an effort to identify targets for prevention. Many guidelines mention infections, exposure to microbes, stress, pollutants, allergens, and tobacco smoke as possible contributing factors. The development of allergen-specific IgE, especially if it occurs in early life, is an important risk factor for asthma, especially in developed countries (17).

Unfortunately, to date this knowledge has not translated into successful programs for primary prevention. Although increased exposure to mainly indoor allergens has been implicated in the development of asthma through induction of allergic sensitization (17, 18), current guidelines avoid giving specific recommendations, as the few existing intervention studies have produced conflicting results (19–21). Avoidance of exposure to tobacco smoke during pregnancy and infancy is the only properly documented modifiable environmental factor that can be safely recommended for the primary prevention of asthma (Evidence B). Other, potentially useful, interventions, such as maternal diet (22) or vitamin D supplementation (23), require confirmation, whereas agents that would mobilize regulatory immune mechanisms for the primary prevention of asthma (e.g. oral bacterial products, immunomodulators) are being actively pursued (24).

Persistent asthma is universally regarded as a disease of chronic airway inflammation. Increased populations of mast cells, eosinophils, lymphocytes, macrophages, dendritic cells, and others contribute to inflammation (25, 26). Structural cells such as epithelial cells and smooth muscle cells may also contribute to the inflammatory milieu (27, 28). The inflammatory and structural cells collectively produce mediators such as cytokines, chemokines, and cysteinyl leukotrienes that intensify the inflammatory response and promote airway narrowing and hyperresponsiveness (29). AHR is associated with excessive smooth muscle contraction in response to nonspecific irritants and viral infections, and for allergic individuals, exposure to specific allergens (30, 31). Neural mechanisms, likely initiated by inflammation, contribute to AHR (32).

Acute episodes of airway narrowing are initiated by a combination of edema, infiltration by inflammatory cells, mucus hypersecretion, smooth muscle contraction, and epithelial desquamation. These changes are largely reversible; however, with disease progression, airway narrowing may become progressive and constant (33). Structural changes associated with airway remodeling include increased smooth muscle, hyperemia with increased vascularity of subepithelial tissue, thickening of basement membrane and subepithelial deposition of various structural proteins, and loss of normal distensibility of the airway (34, 35). Remodeling, initially described in detail in adult asthma, appears to be also present in at least the more severe part of the spectrum in pediatric asthma (36, 37).

Research Recommendations

- Increased efforts for understanding the mechanisms of pediatric asthma are clearly needed
- The basic mechanisms underlying pediatric asthma phenotypes/endotypes should be better characterized
- The presence and progression of airway remodeling in different pediatric asthma phenotypes/endotypes requires considerable effort
- Primary prevention should be the focus of intensive research. Early life and/or pregnancy are evident targets
- Secondary prevention, especially in children with atopic dermatitis, may also result in improved outcomes




Figure 2 In children, as in adults, pathological changes of the bronchi ('airway remodeling'), are present in the airways. Inflammation is triggered by a variety of factors, including allergens, viruses, exercise etc. These factors also induce hyperreactive

responses in the asthmatic airways. Inflammation and hyperreactivity lead to airway obstruction. Although pathophysiological changes related to asthma are generally reversible, partial recovery is possible.

Guideline Update Recommendations

- Pathophysiological mechanisms have a background role in guidelines. Nevertheless, current knowledge on bronchial inflammation and remodeling in children can be detailed

Natural history

Asthma may persist or remit and relapse (38). Natural history and prognosis are particularly important in children, because a considerable proportion of children who wheeze outgrow their symptoms at some age (39). The likelihood of long-term remission, on the one hand, or progression and persistence of disease, on the other, has received considerable attention in the medical literature over the last decade (40–42). However, the natural history of asthma, with the exception of the common understanding that asthma starts early in life and may run a chronic course, is not prominent in many current guidelines.

The most detailed reference to natural history is made in the NAEPP. Among children who wheeze before the age of 3 years, the majority will not experience significant symptoms after the age of 6 years. Nevertheless, it appears that decrements in lung function occur by the age of 6 years, predominantly in those children whose asthma symptoms started before 3 years of age. The Asthma Predictive Index (API) uses parental history of asthma and physician diagnosis of atopic dermatitis as major criteria, along with peripheral blood eosinophilia, wheezing apart from colds, and physician

diagnosis of allergic rhinitis as minor criteria, to predict disease persistence at the age of 6 years, in children younger than 3 years with a history of intermittent wheezing (43). As shown in at least three independent populations (43–45), the API holds a modest ability to predict disease persistence into early school age and is also recommended by GINA <5 (Evidence C). However, extrapolation of findings from epidemiological studies to the assessment of future risk in individual patients in the clinical setting, or in different populations, may not be as straightforward (46).

PRACTALL also stresses the variable natural history patterns of recurrent wheezing in early childhood. Infants with recurrent wheezing have a higher risk of developing persistent asthma by the time they reach adolescence, and atopic children in particular are more likely to continue wheezing. In addition, the severity of asthma symptoms during the first years of life is strongly related to later prognosis. However, both the incidence and period prevalence of wheezing decrease significantly with increasing age.

Research Recommendations

- Predictive (bio)markers of persistence are needed
- It will be beneficial to further characterize the stability/natural history of pediatric asthma phenotypes
- The relationships between inception, exacerbations, and remodeling should be explored in childhood asthma
- Further research into asthma predictive indices may improve their performance and/or generalize their applicability

- The effect of guideline-proposed treatment on the natural history of asthma warrants further study

Guideline Update Recommendations

- Natural history is an important element of pediatric asthma requiring more attention
- The evaluation of risk for persistence should be emphasized

Diagnosis

History of recurrent episodes of wheezing is universally accepted as the starting point for asthma diagnosis in children. The required number/rate of such episodes is generally not specified, although an arbitrary number of three or more has been proposed. Typical symptom patterns are important for the establishment of the diagnosis. These include recurrent episodes of cough, wheeze, difficulty in breathing, or chest tightness, triggered by exposure to various stimuli such as irritants (cold, tobacco smoke), allergens (pets, pollens, etc.), respiratory infections, exercise, crying, or laughter, appearing especially during the night or early morning (Evidence A–B). Personal history of atopy (e.g. eczema, allergic rhinitis, or food/aeroallergen sensitization) and family history of asthma strengthen the diagnosis (Table 2).

Taking into account that asthma symptoms are not pathognomonic and may occur as a result of several different conditions, differential diagnosis is very important and includes common childhood problems as well as a long list of mostly infrequent but rather severe diseases, which are listed with minor differences in all guidelines (Table 3).

Evaluation of lung function

Evaluation of lung function is important for both diagnosis and monitoring. Nevertheless, normal lung function tests do not exclude a diagnosis of asthma, especially for intermittent or mild cases (47). Therefore, these tests are considered supportive. Performing the tests when the child is symptomatic may increase sensitivity.

Spirometry is recommended for children old enough to perform it properly; the proposed range of minimum age is between 5 and 7 years. At this time, given the sparse evidence available, decision points do not differ from those used in adults (FEV1: 80% of predicted, reversible after bronchodilation by $\geq 12\%$, 200 ml, or $\geq 10\%$ of predicted); however, these should be re-evaluated. Spirometry may not be readily available in some settings, particularly low-income countries.

Peak expiratory flow (PEF) measurements, including reversibility or variability, may also help support a suspected diagnosis, in children capable of performing them properly. However, NAEPP points out that a normal range for PEF is wide and so it is more useful for monitoring rather than diagnosis.

In children younger than 5 years, newer lung function tests that require less cooperation have been used (such as oscillometry

Table 2 Diagnosis of pediatric asthma

| | |
|--|---|
| History | Recurrent respiratory symptoms (wheeze, cough, dyspnea, chest tightness) typically worse at night/early morning exacerbated by exercise, viral infection, smoke, dust, pets, mold, dampness, weather changes, laughing, crying, allergens |
| | Personal history of atopy (eczema, food allergy, allergic rhinitis) |
| | Family history of asthma or atopic diseases |
| Physical examination | Chest auscultation for wheezing |
| | Symptoms/signs of other atopic diseases such as rhinitis or eczema |
| Evaluation of lung function (spirometry with reversibility testing, preferred to PEF, which can nevertheless be used if resources are limited) | |
| Evaluation of atopy (skin prick tests or serum-specific IgE) | |
| Studies for exclusion of alternative diagnoses (e.g. chest X-ray) | |
| Therapeutic trial | |
| | Evaluation of airway inflammation (FeNO, sputum eosinophils) |
| | Evaluation of bronchial hyperresponsiveness (nonspecific bronchial challenges, e.g. methacholine, exercise) |

To diagnose asthma, confirm the presence of episodic symptoms of reversible airflow obstruction, and exclude other conditions (Table 3). Diagnosis components are listed above in (relative) sequence of importance.

Table 3 Pediatric asthma differential diagnosis

| | |
|--------------------------------------|--|
| Infectious & Immunological disorders | Allergic bronchopulmonary aspergillosis |
| | Anaphylaxis |
| | Bronchiolitis |
| | Immune deficiency |
| | Recurrent respiratory tract infections |
| | Rhinitis |
| | Sinusitis |
| | Sarcoidosis |
| | Tuberculosis |
| Bronchial pathologies | Bronchiectasis |
| | Bronchopulmonary dysplasia |
| | Cystic fibrosis |
| | Primary ciliary dyskinesia |
| Mechanical obstruction | Congenital malformations |
| | Enlarged lymph nodes or tumor |
| | Foreign body aspiration |
| | Laryngomalacia/tracheomalacia |
| | Vascular rings or laryngeal webs |
| | Vocal cord dysfunction |
| Other systems | Congenital heart disease |
| | Gastroesophageal reflux disease |
| | Neuromuscular disorder (leading to aspiration) |
| | Psychogenic cough |

(48) or specific airway resistance (49)); however, these are not generally available outside specialized centers.

Evaluation of AHR and airway inflammation

Airway hyperresponsiveness, assessed by provocation with inhaled methacholine, histamine, mannitol, hypertonic saline, or cold air, has been used in adults to either support or rule out the diagnosis of asthma. The use of these methods in children is supported with reservation by most asthma guidelines. However, accuracy in children is lacking, as the inhaled dose is not adjusted for the size of the patient. Exercise can also be used to assess AHR, but standardization of testing is difficult for children of differing ages (50). These methodological issues have contributed to the tests being mainly limited to use in research rather than clinical practice (51, 52).

Although the guidelines do not stress the utility of obtaining fractional exhaled nitric oxide (FENO) measurements, recent data support that it may be useful as a diagnostic tool. An evidence-based guideline for the use and interpretation of FENO has been recently published (53). It supports the use of FENO to detect eosinophilic airway inflammation, determining the likelihood of corticosteroid responsiveness, monitoring of airway inflammation to determine the potential need for corticosteroid, and unmasking of nonadherence to corticosteroid therapy. However, in many countries, the capacity to measure FENO is unlikely to be available outside specialized centers.

Sputum eosinophils, although promising, have not been supported by data robust enough to make this parameter clinically useful and therefore are not currently recommended for diagnosis or monitoring of childhood asthma.

Evaluation of atopy

There is general consensus that atopy should be evaluated in children when there is a suspicion or diagnosis of asthma. Identification of specific allergic sensitizations can support asthma diagnosis, can indicate avoidable disease triggers, and has prognostic value for disease persistence (52, 54). Both *in vivo* (skin prick tests) and *in vitro* (specific IgE antibodies) methods can be used, considering the ease of performance, cost, accuracy, and other parameters.

Special considerations

There are important differences in the approach to diagnosis according to age. Most guidelines recognize the difficulty in diagnosing asthma in children younger than 2–3 years. In addition to the lack of objective measures at that age, the suboptimal response to medications and variability of natural history make diagnosis in this age-group, at best, provisional (55, 56).

In cases of uncertainty in the diagnosis, particularly in children below the age of 5 years, a short therapeutic trial period (e.g. 3 months) with inhaled corticosteroids is suggested. Considerable improvement during the trial and deterioration

when it is stopped supports a diagnosis of asthma, although a negative response still does not completely exclude the diagnosis (Evidence D).

Although the diversity of childhood asthma is generally recognized and various phenotypes or subgroups are mentioned in different documents, there is little detail or agreement on diagnostic requirements for particular phenotypes, with the exception of exercise-induced asthma.

Research Recommendations

- Identify biomarkers for airway inflammation that are both informative for initial and ongoing treatment decisions and also practical for clinical use
- Diagnostic and prognostic markers for asthma and/or specific phenotypes are clearly needed
- Indirect, noninvasive measures of airway pathology will help the diagnostic investigation in young children
- Development of easy to use lung function tests for young children will improve diagnosis
- Study of lung function cutoff points (FEV1, bronchodilator response) in children is needed

Guideline Update Recommendations

- Newer lung function tests (e.g. oscillometry) may be included as aid to asthma diagnosis in young children
- Pediatric lung function cutoff points should be considered as data become available
- Peripheral airway parameters may be helpful in the diagnostic evaluation
- The role of FENO in diagnosis and monitoring can be reevaluated
- The role of AHR assessment in clinical practice should be clearly defined

Principles of pediatric asthma management

Although there is considerable variation in the way that different guidelines structure and present the principles and components of asthma management, the key messages are consistent, including a number of components that are a consequence of its chronic and variable course (Fig. 3).

Patients and their parents or caregivers should be educated to optimally manage the disease, in collaboration with healthcare professionals. Education and the formation of a partnership between them are crucial for the implementation and success of the treatment plan (Evidence A–B).

Identification (Evidence A) and avoidance (Evidence B–C) of specific (i.e. allergens) and nonspecific triggers (e.g. tobacco smoke, but not exercise) and risk factors are also of significant importance, because these may drive or augment inflammation.

Assessment and monitoring should be performed regularly because of the variable course of asthma and importantly to reevaluate and fine-tune treatment (Evidence A–B).

Pharmacotherapy is the cornerstone of treatment. The optimal use of medication can, in most cases, help patients control their symptoms and reduce the risk for future morbidity.




Figure 3 Asthma management should be 'holistic', including all the elements necessary to achieve disease control: patient and parent education, identification and avoidance of triggers, use of appropriate medication with a well-formed plan, and regular monitoring, are all crucial for success. Management should be adapted to the available resources.

Allergen-specific immunotherapy should be considered for children whose symptoms are clearly linked to a relevant allergen (Evidence B).

The management of asthma exacerbations is a major consideration, independent of chronic treatment.

There is a trend toward considering phenotype-specific treatment choices; however, there is as yet no consistent approach to this. Exercise-induced asthma is recognized in all guidelines, and specific instructions are suggested for its management. In addition, the specific challenges of treating severe and difficult asthma are highlighted throughout the documents. Age-specific instructions are usually proposed in 2 or 3 strata. It is generally accepted that recommendations in the youngest age-group are based on very weak evidence.

Overall, the treatment goal is disease control, including reduction in future risk of morbidity such as exacerbations. In the past, there were suggestions that early treatment may be able to alter the natural course of the disease; however, a number of recent studies (57–59) have shown that even prolonged treatment with inhaled corticosteroids, despite its many benefits (60), is unable to do so (Evidence A). Allergen-specific immunotherapy is currently the only treatment with long-term disease-modifying potential (61–63); however, the evaluation of the evidence base for this effect is controversial among experts and therefore needs further studies.

Research Recommendations

- Whether phenotype-specific management strategies can be more effective than currently used ones should be investigated
- Diagnosis, management, and treatment for severe asthma require additional effort

Guideline Update Recommendations

- Phenotype-specific management principles can be useful
- Probabilistic models, taking into account future risk, may be helpful in guideline design

Education

Asthma education should not be regarded as a single event but rather as a continuous process, repeated and supplemented at every subsequent consultation. There is general consensus on the basic elements of asthma education: it should include essential information about the (chronic/relapsing) nature of disease, the need for long-term therapy, and the different types of medication ('controllers' and 'relievers'). Importantly, education should highlight the importance of adherence to prescribed medication even in the absence of symptoms and should involve literal explanation and physical demonstration of the optimal use of inhaler devices and peak flow meters. Education should be tailored according to the sociocultural background of the family (64).

Education for self-management is an integral part of the process (Evidence A); it does not intend to replace expert medical care, but to enable the patient and/or the caregiver to help reach and maintain control of asthma, forming a functional partnership with the healthcare professional in dealing with daily aspects of the disease. This involves the ability to avoid or manage identifiable triggers, such as infections, allergens, and other environmental factors (e.g. tobacco smoke).

The use of a written, personalized management plan is generally recommended (Evidence B); the term 'asthma action plan' is most commonly used. This should optimally include the daily medication regimen, as well as specific instructions for early identification and appropriate management of asthma exacerbations or loss of asthma control. Educated interpretation of symptoms is of primary importance, as well as the use of PEF monitoring values as a surrogate measure of current asthmatic status (Evidence A), although this may be challenging in younger children. Supplemental material and/or links to information resources for structured templates and further guidance are available in several documents (AAMH, GINA, NAEPP, and SIGN). Unfortunately, the uptake of written action plans is poor, both by patients and by practitioners.

It is generally recognized that different approaches should be sought for different age-groups; in particular, JGCA and PRACTALL recommend an age-specific stratification of educational targets, with incremental participation of older children in self-management programs.

Most educational interventions have been shown to be of added value (and thus should be intensely pursued) mainly in patients with moderate or severe asthma; milder cases may benefit as well, but clinical effect is more difficult to formally demonstrate.

Primary asthma education in the office/clinic may be complemented by educational interventions at other sites. School-

based programs (65), often peer-led in the case of adolescents, may have increased penetration and acceptance in large numbers of asthmatic children (Evidence B). Patients and their families may also be provided brief, focused educational courses when being admitted to hospital emergency departments for asthma exacerbations, while use of computer- and Internet-based educational methods represent other proposed alternatives, especially for older children and adolescents (Evidence B).

Focused training in pharmacies and education of the general public receive relatively less priority by current guidelines. Finally, education of health authorities and politicians is only mentioned by PRACTALL. Education of healthcare professionals is self-evident.

Research Recommendations

- Educational programs largely depend upon local culture; therefore, local versions, based on these principles, should be developed
- Improving uptake of asthma management plans, both by families and by practitioners, is needed

Guideline Update Recommendations

- Implementation strategies on a local and national level should be explored
- Tailoring education according to the sociocultural level of the patient's parents may have important practical consequences

Trigger avoidance

Asthma symptoms and exacerbations are triggered by a variety of specific and nonspecific stimuli. It is reasonable that avoidance of these factors may have beneficial effects on the activity of the disease. The airway pathophysiology mediated through IgE to inhalant allergens is widely acknowledged; however, not every allergen is equally significant for all patients. Thus, there is general consensus that sound allergological workup (including careful history for the assessment of clinical relevance, skin prick testing, and/or specific IgE measurement) should precede any effort to reduce exposure to the corresponding allergen (Evidence B).

There is some ambiguity with respect to the role of allergen avoidance. Some documents (JGCA, NAEPP3, and PRACTALL) provide specific recommendations for the reduction in allergen exposure for sensitized patients with asthma. Indoor allergens (dust mite, pet, cockroach, and mold allergens) are considered the main culprits and are targeted by specific interventions (Evidence B–D, depending on allergen and intervention). Other guidelines (AAMH, GINA, and SIGN) are more cautious in the interpretation of the evidence and underline the unproven effectiveness of current avoidance strategies on asthma control. Complete allergen avoidance is usually impractical, or impossible, and often limiting to the patient, and some measures involve significant expense and inconvenience. Moreover, the pre-

vailing view is that single interventions for indoor allergens have limited effectiveness; if measures are to be taken, a multifaceted, comprehensive approach is prerequisite for clinical benefit (Evidence A), while tailoring environmental interventions to specific sensitization profiles has been shown to be of added value (66). Outdoor allergens are generally less manageable, because their levels cannot be modified by human intervention and staying indoors for appropriate periods may be the only recommendable approach.

Indoor and outdoor pollution can be major triggers particularly in developing countries (67). It is clear that smoking cessation in adolescents and reduction in exposure to environmental tobacco smoke, as well as to various indoor and outdoor pollutants and irritants, should be attempted in children with asthma (Evidence C). Vigorous measures are needed to achieve avoidance. Likewise, in the relatively uncommon case of drug-sensitive (e.g. NSAIDs) or food-sensitive (e.g. sulfites) children with asthma, complete avoidance should be advised, but only after thoroughly assessing the causality.

Research Recommendations

- Additional trials of multifaceted interventions may help clarify the role of allergen avoidance
- Assessment of personal exposure is crucial to quantitate any effect

Guideline Update Recommendations

- Local environmental differences in relation to exposures should be emphasized

Pharmacotherapy

The goal of asthma treatment is control using the least possible medications. Asthma pharmacotherapy is regarded as chronic treatment and should be distinguished from treatment for acute exacerbations that is discussed separately.

In the initial assessment, and especially if the patient has not received asthma medication before, there is a unique opportunity to evaluate disease severity. Most guidelines propose the use of severity as the criterion for selecting the level of treatment at the first assessment. GINA omits this step in this edition, while PRACTALL suggests that both severity and control can be used.

After the initial assessment, pharmacological therapy is selected through a stepwise approach according to the level of disease control. In evaluating control, the differentiation between current impairment and future risk is considered in NAEPP and GINA. This additional consideration is important in appreciating the independence of these elements.

If control is not achieved after 1–3 months, stepping up should be considered, after reviewing device use, compliance, environmental control, treatment for comorbid rhinitis, and, possibly, the diagnosis. When control has been achieved for

at least 3 months, stepping down can be considered (Evidence A–B).

Drug classes and their characteristics

Despite the progress in asthma research, current asthma medications belong to a small range of pharmacological families. Corticosteroids, beta-2 adrenergic agonists, and leukotriene modifiers are the predominant classes. Chromones and xanthines have been extensively used in the past but are now less popular, the former because of limited efficacy and the latter because of frequent side effects. Omalizumab, a monoclonal antibody against IgE, is the newest addition to asthma medications, the first from the family of immunomodulatory biological agents, of which several other molecules are currently under evaluation in clinical trials. Medications are classified, according to their use, as those used for acute relief and those used for long-term control.

Medications used for acute relief of symptoms

'Relievers' are used for the acute, within minutes, relief of asthma symptoms, through bronchodilation. Use of inhaled short-acting beta-2 adrenergic agonists (SABA), most commonly salbutamol, as first-line reliever therapy is unanimously promoted for children of all ages (Evidence A). They are typically given on an 'as needed' basis, although frequent or prolonged use may indicate the need to initiate or increase anti-inflammatory medication. Compared to other relievers, SABA have a quicker and greater effect on airway smooth muscle, while their safety profile is favorable; a dose-dependent, self-limiting tremor and tachycardia are the most common side effects.

Oral SABA are generally discouraged. Anticholinergic agents, mainly ipratropium, are second-line relievers, but are less effective than SABA.

Medications used for long-term asthma control

Inhaled corticosteroids (ICS). The use of ICS as daily controller medications in persistent asthma is ubiquitously supported, as there is robust evidence that therapeutic doses of ICS improve symptoms and lung function, decrease need for additional medication, and reduce rate of asthma exacerbations and asthma-induced hospital admissions in children of all ages (68). Because of their pleiotropic anti-inflammatory activity, initiation of ICS therapy generally constitutes the first step of regular treatment (Evidence A).

Most children with mild asthma can be well controlled with low-dose ICS (Table 4). Although dose–response curves have not been established for every ICS formulation and for all age-groups, efficacy appears to reach a plateau for most patients and outcomes around or below medium dose range (69, 70). It should be noted, however, that the evidence on the role of low-dose ICS as maintenance treatment for the prevention of intermittent, virus-induced

Table 4 Inhaled steroid (ICS) dose equivalence

| Drug | Low daily dose (µg) |
|---------------------------------|---------------------|
| Beclomethasone dipropionate HFA | 100 |
| Budesonide | 100 |
| Budesonide (nebulized) | 250 |
| Ciclesonide | 80 |
| Flunisolide | 500 |
| Flunisolide HFA | 160 |
| Fluticasone propionate HFA | 100 |
| Mometasone furoate | 100 |
| Triamcinolone acetonide | 400 |

Inhaled steroids and their entry (low) doses. Medium doses are always double (2×), while high doses are quadruple (4×), with the exception of flunisolide and triamcinolone which are 3×.

wheezing in young children is limited and controversial (71).

After control has been achieved, patients should be gradually titrated down to the lowest effective dose. The clinical response may vary among patients; therefore, the optimal maintenance dose is sought on an individual basis.

The clinical benefit of ICS must be balanced against potential risks, with linear growth remaining the dominant concern. Several studies in older children have consistently demonstrated a modest but significant effect (~1 cm in the first year) (59, 72, 73), while studies in preschool-age children are less consistent. The effect appears to improve with time; however, there are concerns about subgroups who may be more susceptible or permanently affected (59, 74). Recent data from the CAMP study suggest that an effect on adult final height cannot be excluded (75).

Risks for subcapsular cataracts or bone mineral density reduction in childhood are very low.

Most of the information available refers to low to medium doses, and there is minimal information on high-dose ICS. Furthermore, the total steroid load in cases of concomitant use of local steroids for allergic rhinitis or eczema should be taken into account.

Inhaled steroids differ in potency and bioavailability; however, because of both a relatively flat dose–response relationship in asthma and considerable interpersonal variability, few studies have been able to confirm the clinical relevance of these differences.

Leukotriene receptor antagonists (LTRA). Among leukotriene modifiers, montelukast is available worldwide; zafirlukast is mentioned only in NAEPP and pranlukast only in JGPA. LTRA are effective in improving symptoms and lung function and preventing exacerbations at all ages (76, 77) (Evidence A). They are generally less efficacious than ICS in clinical trials, although in some cases noninferiority has been shown (78, 79). Furthermore, there is evidence suggesting particular effectiveness of montelukast in exercise-induced asthma, possibly superior to other treatments (80). Therefore,

in most guidelines they are recommended as second choice after low-dose ICS, or occasionally as 'alternative first-line treatment' (AAMH, PRACTALL), for the initial step of chronic treatment. In the context of the next treatment steps, they are also effective as add-on medications, but less so in comparison with LABA (81). PRACTALL also suggests that LTRA may be particularly useful when the patient has concomitant rhinitis.

Montelukast is relatively free of adverse effects. With zafirlukast, signs of hepatic dysfunction should be monitored.

Long-acting beta-2 adrenergic agonists (LABA). LABA, including salmeterol and formoterol, have long-lasting bronchodilator action. In older children and adults, ICS-LABA combinations have been shown to improve asthma outcomes to a better extent than higher doses of ICS (82–84). However, a small, but statistically significant risk for severe exacerbations and death associated with daily use of LABA has been described (85–87). Furthermore, the evidence base of the efficacy of ICS-LABA combinations in young children is not as robust as that of older children and adults (88, 89). These concerns are probably behind the rather controversial position of LABA in pediatric asthma treatment.

All documents agree that LABA should only be prescribed in combination with ICS and are therefore relevant as add-on treatment. In some cases, ICS-LABA combinations are recommended as the preferred add-on treatment in children >5 years (SIGN, GINA), or >12 years (NAEPP), in other they are suggested as an option for children >5 years (AAMH, NAEPP) or at any age (JGPA), while in other as an add-on treatment at a subsequent step (PRACTALL); GINA <5 does not recommend them for children <5 years because of the lack of data.

In the absence of data of safety and efficacy in children younger than 5 years, it is probably better to be cautious, until such data are produced. For older children, it is clear that ICS+LABA are an important treatment option, preferable for at least a subpopulation of patients (90). It is important to appreciate the right balance between risk and benefits of therapy (91, 92).

The use of a single combination inhaler, rather than separate inhalers, is generally recommended to maximize adherence and efficacy and reduce the possibility of overuse of LABA and underuse of ICS with potential for serious side effects.

Taking advantage of the fast action of formoterol, a strategy proposing the use of a single inhaler for both reliever and controller medication (SMART strategy) has been evaluated in several trials, mostly in adults. The efficacy has also been shown in children (87, 93).

Chromones. Cromolyn sodium and nedocromil modulate mast cell mediator release and eosinophil recruitment. Several studies have shown some effectiveness in children >5 years; however, evidence is not robust (94, 95). They are administered 3–4 times a day and are certainly less effective than ICS. On the other hand, they have an excellent safety

profile. On the basis of these, chromones are considered having a limited role, but are 'traditionally' included in most guidelines as second-line medications for mild disease/initial treatment steps and prevention of exercise-induced asthma. In any case, they are not available anymore in many countries.

Theophylline. Theophylline, the most used methylxanthine, has bronchodilatory properties and a mild anti-inflammatory action. It may be beneficial as add-on to ICS, however, less so than LABA (Evidence B). However, it has a narrow therapeutic index and can have serious side effects, therefore requiring monitoring of blood levels (96). As a result, its role as controller medication is very limited and is only recommended as second-line treatment, where other options are unavailable (96).

Omalizumab. Omalizumab is indicated for children with allergic asthma poorly controlled by other medications (Evidence B). It reduces symptoms and exacerbations and improves quality of life and to a lesser extent lung function (97–100).

Strategies for asthma pharmacotherapy

Detailed strategies for prescribing asthma medications are proposed in all guidelines. Although there are differences on structure and detail between the documents, several common elements can be identified. Age is always taken into account. In infants, the evidence base for treatment is small, and responses are inconsistent and frequently suboptimal. In adolescents, issues that may affect asthma management are mostly related to lack of compliance.

There is consensus that medication for acute relief of symptoms (typically, a short-acting inhaled beta-2 agonist) should be available to all patients with asthma, irrespective of age, severity, or control. The reliever is used as needed; frequent or increased use may indicate lack of control and the need to initiate/step up controller therapy.

A number of steps of controller therapy can be described:

Step 0: In the lowest step, no controller medication is proposed.

Step 1: The next step entails the use of one controller medication. An ICS at low dose is the preferred option in most cases (Evidence A). LTRA are recommended as second option (GINA, GINA < 5, NAEPP, SIGN < 5 years), only if steroids cannot be used (SIGN 5–12 years), equivalent (PRACTALL, AAMH), or even preferred option (JGCA < 5 years). Possible explanations for these variations are that generally ICS are more effective than LTRA in direct comparisons (101, 102), although there are patients that may respond better to LTRA, especially in the younger and less atopic children (103). LTRA have a favorable safety profile and ease of administration and acceptance by the parents and patients (104). Chromones (NAEPP, AAMH, JGCA, and SIGN) and theophylline (in children > 5 years, NAEPP, JGCA, SIGN) are also included as options at this step. However,

chromones are not available anymore in many countries, while, for the reasons mentioned above, theophylline should probably be excluded from this step, with the exception of developing countries where first-line medication may be unavailable or unaffordable.

Step 2: ICS can be increased to a medium dose, or a second medication can be added. This is probably the most variable and to some extent controversial step. For children older than 5 years, GINA and SIGN recommend the combination of ICS+LABA, the JGCA and AAMH documents prefer increasing ICS dose, NAEPP has no preference for children 5–12 years, but recommends either doubling ICS or ICS+LABA for children >12 years, while PRACTALL suggests either doubling ICS or ICS+LTRA. For children younger than 5 years, increasing ICS is the commonest approach (GINA < 5, AAMH, JGCA, and NAEPP); SIGN suggests ICS + LTRA, while PRACTALL suggests either doubling ICS or ICS+LTRA.

Nonetheless, the above variation refers to preferred choices among lists of options that are similar among the documents. With respect to the younger age-group, the small number of studies explains this discrepancy. In older children, choices of safety vs efficacy may influence the recommendations. However, there is good evidence suggesting that the response to medication may differ considerably among individuals (90, 103), suggesting the need for some flexibility in choice and an option to try a different strategy if the first is not successful.

Step 3–4: The subsequent step(s) represent the maximization of conventional treatment, with the use of additional medications and/or further increase in the ICS dose. This may include two distinct steps: In the first, LABA or LTRA (or exceptionally theophylline) are added to the medium-dose ICS, and in the second, the ICS dose is increased (NAEPP, AAMH). Omalizumab is also considered at this step by NAEPP.

Step 5: In cases where control cannot be achieved with the maximum dose of inhaled corticosteroids and additional medication, the final resort is the use of oral corticosteroids. This step is not always part of the algorithm (JGCA, AAMH, SIGN < 5 years), possibly because at this stage specialist consultation is warranted. GINA includes omalizumab here.

All guidelines recommend that asthma education, avoidance of triggers, evaluation of compliance, and correct use of inhaler device, and even reconsideration of the diagnosis, should be carried out before stepping up treatment, in children in whom control is difficult to achieve. In addition, concomitant diseases, such as allergic rhinitis, should always be taken into account (105).

On the basis of the above, a simplified algorithm is shown in Fig. 4.

It should be noted that in low-income countries, an important obstacle to asthma management is the cost of medications. Essential asthma drugs (SABA and ICS) are proposed by The Union Asthma Guidelines (106).

Delivery devices

In addition to the selection of medication, understanding and selection of the optimal device for inhaled drug delivery is an important consideration. Devices fall under three categories: pressurized meter-dose inhalers (pMDI), dry powder inhalers (DPI), and nebulizers. Breath-actuated MDIs have distinct characteristics. There is no robust evidence suggesting major differences in effectiveness between the device types; however, each type has specific merits and limitations (107). There is general consensus that prescription of a device should be individualized, with major criteria being the patient's ability to use, preference, and cost. A detailed review of different devices has been recently published (108). Training is vital (109). pMDI and DPI are preferred to nebulizers, as they are at least equally effective (110, 111), cheaper, and easier to use and maintain. Spacers should always be used with MDIs in 0- to 5-year-olds and in exacerbations; they are also preferable in older children. Care needs to be taken to minimize static charge in plastic spacers (112). A mouthpiece should substitute for the mask when the child is able to use it. In areas where commercially produced spacers are unavailable or unaffordable, a 500-ml plastic bottle spacer may be adapted to serve as an effective spacer for children of all ages (113). The effects of anatomical differences and low inspiratory flows of young children on medication deposition by different drug delivery devices and spacers are not well understood.

Taking the above into account, a simplified selection scheme is shown in Box 2.

Research Recommendations

- Clinical trials should be designed to evaluate individual responses to different medications in asthma
- Measurable predictors of response to different therapies should be developed
- New strategies with existing medications should be studied, especially in the youngest age-group
- More data are needed on medication deposition by different delivery devices and spacers in young children
- The role of immunomodulators on asthma treatment can be expanded

Guideline Update Recommendations

- The individual response to different medications, frequently responsible for treatment failures, should be stressed in future documents
- More detailed recommendations on stepping down/stopping treatment are needed
- The position of chromones and theophylline should be reevaluated
- The possibility of moving between medications of the same step can be considered
- Strategies for the assessment of compliance with inhaler therapy should, when possible, be incorporated in treatment plans




Figure 4 The stepwise approach to asthma treatment in childhood aims at disease control. Reliever medication should be used at any level of severity/control, if symptoms appear/exacerbate. At the mildest spectrum of the disease, no controller medication is needed (step 0). The next step entails the use of one controller medication (step 1). If this is not enough, two medications, or a double dose of inhaled steroid, can be used (step 2). In more difficult cases, increase of inhaled steroid dose, alone or in combination with additional medication is needed (step 3–4). Oral corticosteroids are kept as the last resort, for very severe patients (Step 5). Among biological treatments, omalizumab has specific indications for children at step 3 or higher. Stepping up or down

should be evaluated at regular intervals, measured by level of control. Treatment adherence, exposure to triggers and alternative diagnoses should always be considered before stepping up. It should be stressed that medications in each step are not identical, in either efficacy or safety, and preferred choices can be described, especially for different age groups. For more details on this, the reader is referred to the text. Nevertheless, there is also considerable variation in the individual response to each medication, therefore, close monitoring and relevant adjustments are equally or even more important. An easy way to memorize this stepwise approach is that the number of each step suggests the number of medications, or ICS level, to be used.

Box 2

Inhaled medication delivery devices

0 to ~5 years

pMDI with static-treated spacer and mask (or mouthpiece as soon as the child is capable of using)

>~5 years

Choice of: pMDI with static-treated spacer and mouthpiece, DPI (rinse or gargle after inhaling ICS), breath-actuated pMDI (depending on patient ability to use, preference)

Nebulizer: second choice at any age

Immunotherapy

Allergen-specific immunotherapy (SIT) involves the administration of increasing doses of allergen extracts to induce persistent clinical tolerance in patients with allergen-induced symptoms. Subcutaneous immunotherapy (SCIT) has been shown to be clinically effective in allergic asthma, leading to a significant reduction in symptoms, airway hyperresponsiveness, and medication requirements (Evidence A–B). These effects are generally considered to be greatest when standardized, single-allergen extracts of house dust mites, animal dander, grass, or tree pollen are administered, whereas definitive evidence is currently lacking for the use of multi-allergen extracts and for mold and cockroach allergens (114, 115).

In clinical practice, allergen is typically administered for 3–5 years. A specific age limit, above which SIT can be initiated, has not been clearly defined; PRACTALL suggests that it may represent an acceptable intervention above 3 years of age, while GINA <5 years suggests that no recommendation can be made at this age, because of scarce evidence.

SIT has some important advantages over conventional pharmacological treatment (116); first, it is the closest approach to a causal therapy in allergic asthma; second, its clinical effect has been shown to persist after discontinuation of treatment (61, 62); and third, SIT has been linked with a preventive role against the progression of allergic rhinitis to asthma and the development of sensitization to additional allergens (63, 117). However, several experts feel that these aspects of SIT have not been adequately demonstrated.

Nevertheless, convenience and safety of administration have been a matter of concern. Apart from common local side effects at the injection site, systemic reactions (including severe bronchoconstriction) may occasionally occur, and these are more frequent among patients with poor asthma control (118). It is therefore generally agreed that SIT should only be administered by clinicians experienced in its use and appropriately trained to identify and treat potential anaphylactic reactions. Furthermore, SIT is not recommended in severe asthma, because of the concern of possible greater risk for systemic reactions.

Clinical benefits of SIT are differentially weighed against safety issues, so some recommendations vary between guidelines. AAMH, SIGN, and NAEPP acknowledge a clear role for immunotherapy as an adjunctive treatment, provided that clinical significance of the selected allergen has been demonstrated. PRACTALL also endorses immunotherapy and further suggests SIT to be considered as a potential preventive measure for the development of asthma in children with allergic rhinitis. According to GINA, the option of immunotherapy should only be considered when all other interventions, environmental and pharmacologic, have failed. However, in such unresponsive condition, the efficacy of immunotherapy is neither warranted.

In the context of ICON, the discussion on the role of SIT in childhood asthma has also been controversial. It is clear

that additional studies are needed to be able to provide clear recommendations in the future.

Sublingual immunotherapy (SLIT) is painless and child-friendly in terms of administration route, offering the desirable option of home dosing and a more favorable safety profile compared to SCIT. Most documents require additional evidence of efficacy before recommending SLIT as a valid therapeutic option in asthma management. Nevertheless, a relevant meta-analysis confirmed significant efficacy in children with asthma (119).

Research Recommendations

- The long-term effects of SIT in young children, including its asthma-preventing capacity, should be further investigated
- Large studies of SLIT in pediatric asthma are needed
- Identification of surrogate markers for response to treatment should be sought

Guideline Update Recommendations

- Comparisons of SIT with pharmacotherapy should be taken into account
- A recommendation on SLIT may be considered

Monitoring

When asthma diagnosis has been confirmed and treatment initiated, ongoing monitoring of asthma control is strongly recommended (Evidence B–C). Control can be assessed at regular intervals, based on the components described in Table 1. Generally, only minimal symptoms are acceptable. For patients on daily controller therapy, reviews approximately every 3 months are suggested; after an exacerbation, a shorter interval should be considered (Evidence D). Several validated tools for assessing asthma control in children have been published (120–124).

Spirometry is recommended as a valuable measure for monitoring lung function in children who can perform it (Evidence B). Peak expiratory flow monitoring is recommended as an option for assessing control and home monitoring of more severe patients, or those with poor perception of severity (Evidence B).

Monitoring adherence to asthma therapy and assessment of inhaler technique are important (109, 125, 126). Self-mon-

itoring at home (e.g. symptoms, PEF), as part of a personal management plan, is encouraged.

Additional recommendations, not uniformly suggested, include monitoring of quality of life (AAMH, NAEPP, and SIGN) (Evidence C), and of adverse effects of asthma therapy, particularly growth rate (AAMH, NAEPP, PRAC-TALL, and SIGN). Multiple monitoring methods may be useful in some cases.

Monitoring FENO is not recommended by the referenced pediatric asthma guidelines; however, it has been recently favorably reevaluated (94, 127). In contrast, the role of monitoring bronchial hyperresponsiveness or induced sputum eosinophilia is not currently well established (128–131).

Monitoring should continue/intensify after stepping down or pausing controller therapy.

Research Recommendations

- The kinetics of airway inflammation and BHR should be better understood and their role in monitoring identified
- Identification of additional noninvasive markers of airway inflammation, relevant to clinical management, will be useful

Guideline Update Recommendations

- Newer data on the role of different monitoring tests in improving asthma control can be included
- The role of FENO in monitoring should be reevaluated
- More attention should be given to recommendations about stepping down or stopping controller treatment

Asthma exacerbations (attacks, episodes)

Asthma exacerbations are of critical importance, as they are associated with high morbidity, including emergency visits, hospitalizations, and occasional mortality (132, 133). While detailed criteria for the assessment of severity are proposed (Table 5), there are no objective criteria for the definition of an exacerbation and/or its differentiation from lack of control. The terminology is variable, and the terms ‘exacerbation’, ‘attack’, ‘episode’, or ‘seizure’ (as translated from Japanese) are used almost interchangeably. The optional use of the adjectives ‘acute’ and ‘severe’ suggests that subacute and less severe epi-

Table 5 Assessment of exacerbation severity

| | Mild | Moderate | Severe | Very severe |
|---------------------------------------|--------------------|-------------------------|--|--------------------|
| Wheeze | Variable | Moderate to loud | Loud – on both inhalation and exhalation | Often quiet |
| Breathlessness | Walking | At rest | At rest/sits upright | |
| Speaks in | Sentences | Phrases | Words | Unable to speak |
| Accessory muscle use | No | Common | Marked | Paradoxical |
| Consciousness | Not affected | Not affected | | Agitated, confused |
| Respiratory rate | Slightly increased | Increased | Highly increased | Undetermined |
| Pulse | <100 | <140 (depending on age) | >140 | Bradycardia |
| PEF (% of predicted or personal best) | >60–70 | 40–70 | <40 | <25 |
| SaO ₂ (% on air) | >94–95 | 90–95 | | <90 |
| PCO ₂ (mmHg) | <42 | <42 | | ≥ 42 |

sodes may also be within the limits of the concept. A formal definition is only suggested by GINA < 5. There are descriptive definitions in GINA, NAEP, and AAMH. SIGN includes different algorithmic definitions according to severity (near-fatal asthma, life-threatening asthma, acute severe asthma, moderate asthma exacerbation, and brittle asthma). No definitions are proposed in JGPA and PRACTALL. The acute or subacute and progressive nature of symptom intensification is generally highlighted. It is also generally accepted that the measurement of the associated reduction in airflow is preferable to symptoms in objective assessment. The use of oral steroids is a marker of the presence and/or severity of an exacerbation and has been proposed as part of its definition (134). However, medication use is a result of the exacerbation and therefore cannot formally define it without generating a vicious circle. Taking the above into account, a working definition is shown in Box 3.

Exacerbations can be of varying severity, from mild to fatal, usually graded in three or four categories, from mild to life-threatening. Severity is assessed based on clinical presentation and objective measures (Table 5). Such classification may be difficult to apply in infants and preschool children because of the lack of lung function assessment.

Exacerbation management (Box 4) can take place in different settings: at home, the doctor's office, emergency unit, hospital, or intensive care unit, largely in relation to severity, timing, availability, and organization of medical services.

Bronchodilation is the cornerstone of exacerbation treatment (Evidence A); it should already be started at home, as part of the asthma action plan, and should also be the first treatment measure in the emergency department (ED), immediately following severity assessment. Salbutamol inhaled at doses ranging from 2 to 10 puffs (200–1000 µg), every 20 min for the first hour, given via MDI-spacer (nebulized also possible), is recommended. The addition of ipratropium bromide may lead to some additional improvement in clinical symptoms (Evidence A–B). The response should be assessed after the first hour; if not satisfactory, the patient should be referred to a hospital (if at home) and the next level of therapy should be given.

Administration of supplemental oxygen is important to correct hypoxemia (Evidence A), with parallel O₂ saturation monitoring. In severe attacks, PCO₂ levels may also need to be monitored.

Systemic corticosteroids, preferably oral, are most effective when started early in an exacerbation (Evidence A). The recommended dose is prednisolone 1–2 mg/kg/day, up to 20 mg in children <2 years and up to 60 mg in older children, for 3–5 days. It is pointed out, however, that some recent studies showed negative results using the lower dose. Whether oral steroids should be initiated by parents at home is debated; if this happens, it should be closely monitored by the prescribing physician. Very high-dose inhaled steroids may also be effective either during the exacerbation or preemptively after a common cold (135, 136); however, they are not generally recommended to substitute systemic ones, although some experts feel that this may be an option. There is also some evidence for a modest preemptive effect of montelukast (137); however, this is not currently recommended.

Additional measures at the hospital and/or the intensive care unit include continuous inhaled beta-2 agonists, intravenous bronchodilators such as salbutamol, and aminophylline (Evidence B). There is little or no evidence on magnesium sulfate or helium–oxygen mixture in children; however, these could be options in cases not responding to the above treatments.

Research Recommendations

- Improved asthma exacerbation treatment remains an important unmet need. New medications and/or strategies are needed
- More specific information is needed on dose- and age-appropriate use of anticholinergic therapy in the treatment for asthma
- Evaluation of clinical patterns and/or biomarkers may help making the definition of exacerbations more specific

Guideline Update Recommendations

- The role of high-dose ICS in exacerbations (effective or not) should be clarified
- The follow-up after an exacerbation, including systemic steroid treatment, can be defined in more detail

Box 3

Asthma exacerbation definition

An exacerbation of asthma is an acute or subacute episode of progressive increase in asthma symptoms, associated with airflow obstruction

Box 4

Key points in asthma exacerbation treatment

Bronchodilation: inhaled salbutamol, 2–10 puffs; or nebulized, 2.5–5 mg, every 20' for the first hour, and according to response thereafter

Ipratropium, 2–8 puffs; or nebulized, 0.25–0.5 mg, can be added to salbutamol

If there is no improvement, children should be referred to a hospital

Oxygen supplementation: aim at SaO₂ > 95%

Systemic corticosteroids: oral prednisolone, 1–2 mg/kg/24 h, usually for 3–5 days

At the hospital or ICU, if necessary, consider:

IV beta-2 agonists, IV aminophylline, IV magnesium sulfate, helium–oxygen mixture

Conclusions

Despite significant improvements in our understanding of various aspects of childhood asthma, as well as major efforts in producing high-quality guidelines and/or consensus docu-

ments to support management, millions of patients worldwide continue to have suboptimal asthma control (138), possibly due to suboptimal treatment (139). Regardless of some variability in specific recommendations, wording and structure, all the major documents providing advice for best clinical practice in pediatric asthma management point toward the same core principles and agree among the majority of their choices. However, implementation of such guidelines and access to standard asthma therapy for children remain challenging in many areas of the world.

It is expected, by increasing the accessibility and promoting dissemination of these core principles, in parallel to continued efforts for evaluating and incorporating evidence into improved guidelines, that we will be able to help improve the quality of life of children with asthma and to reduce the burden of this contemporary epidemic. Further understanding of the underlying pathophysiology and improved classification of subtypes may lead to more effective personalized care. Local adaptation of the above principles will also contribute to the same direction (1).

Conflict of interest

N. G. Papadopoulos has received payment for consultancy from Abbott and for lectures from MSD, and grants from Nestle, MSD, Deviblis (EBT). K.-H. Carlsen has served on an international consultatory paediatric board for GSK, and given presentations for GSK, MSD, PolarMed and Schering Plough. A. Custovic has received payment for consultancy and lectures from Novartis and for lectures from GlaxoSmithKline, Thermo Fisher Scientific, Airsonet, MSD, and grants from MRC Moulton Charitable Foundation. J. Gern has received payment for board membership from 3V BioSciences, for consultancy from GlaxoSmithKline, Biota, Centocor, Boehringer Ingelheim, MedImmune, Gilead, Theraclone, Synairgen, Pulmatrix, and grants from Merck Inc, Astra Zeneca, GlaxoSmithKline. R. Lemanske has received payment for consultancy from Merck, Sepracor, SA Boney and Associates Ltd, GlaxoSmithKline, American Institute of Research, Genentech, Inc., Double Helix Development, Inc., for lectures from Michigan Public Health Institute, Allegheny General Hospital, American Academy of Pediatrics, West Allegheny Health Systems, Inc., California Chapter 4, AAP, Colorado Allergy Society, Pennsylvania Allergy and Asthma Association, Harvard Pilgrim Health, California Society of Allergy, NYC Allergy Society, World Allergy Organization, American College of Chest Physicians, AAAAI, for Employment from University of Wisconsin School of Medicine and Public Health, for Royalties from Elsevier, and grants from National Heart Lung and Blood Institute, Pharmaxis. P. Le Souef has received a grant from AstraZeneca. G. Roberts is a member of the steering committee for the GAP trial, paid by ALK. C. A. Akdis has received payment for consultancy from Actellion, Aventis, Stallergenes, Allergopharma, Circacia, Swiss Institute of Allergy and Asthma Research, University of Zurich, Switzerland, and grants from Novartis Research on immunoregulation in asthma, PREDICTA: European Commission's

Seventh Framework programme No. 260895 Research on virus induced exacerbations, Swiss National Science Foundation Research on T cell interaction with the epithelium, MeDALL: European Commission's Seventh Framework Programme No. 261357 Research on early initiation of asthma, Christine Kühne-Center for Allergy Research and Education Research on severe allergies. L. B. Bacharier has received payment for consultancy from Aerocrine, GlaxoSmithKline, Genentech/Novartis, Merck, Schering, Cephalon and for lectures from Aerocrine, AstraZeneca, Genentech, GlaxoSmithKline, Merck, Schering. J. de Blic is member of the steering committee for the GAP trial, paid by ALK. He is also a member of the advisory board on asthma in children for GSK, MSD, CHIESI, and Stallergenes. W. Burks has consulted for Dannon Co. Probiotics, Exploramed Development LLC, Intelliject, McNeil Nutritionals, Merck & Co., Novartis, Nutricia, Pfizer, Portola Pharmaceuticals and Schering-Plough; has received grants from the Food Allergy and Anaphylaxis Network, the Food Allergy Initiative, the NIH, the National Peanut Board, SHS, and the Wallace Research Foundation; and owns stock or stock options in Allertein and Mast Cell, Inc. T. B. Casale has received payment for consultancy from MedImmune. J. A. Castro-Rodriguez has received payment for development of educational presentation from AZ, GSK, MSD, Novartis. T. Frischer has worked on a national advisory board for MSD. T. W. Guilbert has received honoraria from GlaxoSmithKline, AstraZeneca, PeerPoint Medical Education Institute, Merck, and Antidote; has received research support from Altus Pharmaceuticals, Inspire Pharmaceuticals, and the National Institutes of Health; and is a member of the American Lung Association, the American Thoracic Society, and the American Academy of Pediatrics. P. W. Heymann has received payment for Employment from University of Virginia and grant from NIH/U01 grant. D. J. Jackson has received payment for consultancy from Gilead and grants from NIH, AAAAI/GlaxoSmithKline, Pharmaxis. O. Kalayci has received payment for consultancy from MERCK and received lecture fee from Grupo Uriach Pharma, and grants from Turkish National Science Foundation, Hacettepe University. S. Kling has received payment for Ethics lectures from MSD (Merck) and travel expenses from Cipla Medpro with Sponsorship to Allergy Society of South Africa (ALLSA) Congress 2010; money paid to ALLSA. P. Kuna has received payment for board membership and for lectures from AstraZeneca, Boehringer, MSD, and lecture fee from GSK, Adamed. S. Lau has received payment for consultancy from Merck, for lectures from Symbiopharm, Novartis, ALK, AstraZeneca, and grants from SymbioPharm, Airsonett. D. K. Ledford has received payment for consultancy from Genentech, for expert testimony from Shook Hardy & Bacon, and grants from Forest Pharmaceuticals, Viro Pharma. A. H. Liu has served on the speakers' bureau for Merck, Aerocrine, and Phadia; has served on the speakers' bureau and advisory board for GlaxoSmithKline and AstraZeneca; and has received a research grant from Novartis. R. F. Lockey has received payment for Board membership from the World Allergy Organization, for consultancy from

Merck, ALK, for employment from the University of Florida, VA Hospital, for expert testimony from two law firms, and received grants from ALA, Pharmaceuticals. He has also received payment for lectures from Merck, AstraZeneca, royalties from Informa Publishing, for travel expenses to World Allergy Organization meetings, international congresses for presenting lectures; and owns stock or stock options in Roth IRA acct. K. Lødrup Carlsen has received payment for lectures from GlaxoSmithKline in the last year (once) and grants from National and regional grants for research in our group. J. Lötvald has consulted for GlaxoSmithKline, Novartis, and Merck; has received grants from GlaxoSmithKline; and has received payment for lectures from AstraZeneca, GlaxoSmithKline, Novartis, and Merck. A. Nieto has received payment for board membership, consultancy and lecture fee from Novartis Pharma, MEDA Pharma, CBF LETI, MSD, Allergopharma, and also for development of educational presentations from Schering-Plough and grants from Immunotek. P. Pohunek has received lecture honoraria from AstraZeneca, GSK, MSD, UCB Pharma and travel support for scientific meetings by AstraZeneca, GSK, MSD and Chiesi. D. Price has consultant arrangements with Boehringer Ingelheim, GlaxoSmithKline, Merck, Mundipharma, Novartis and Teva; he or his research team have received grants and support for research in respiratory disease from the following organizations in the last 5 years: UK National Health Service, Aerocrine, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck, Mundipharma, Novartis, Nycomed, Pfizer and Teva. He has spoken for Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Merck, Mundipharma, Pfizer and Teva, he has shares in AKL Ltd., which produces phytopharmaceuticals, and he is

the sole owner of Research n Real Life Ltd. N. Rosario has received payment for board membership from Sanofi Aventis, Takeda, MSD, for consultancy from MSD, Sanofi Aventis, GSK, for lectures from MSD, Sanofi Aventis, GSK, Takeda, Aché, Danone and for development of educational presentations from MSD, Sanofi Aventis, Danone. L. J. Rosenwasser has received payment for board membership from WAO and for consultancy from Genentech, Novartis, AZ, Regeneron, Sanofi. R. Stein has received payment for lectures from Abbott. S. Szefer has received payment for consultancy from Merck, Genentech, Schering, Boehringer-Ingelheim, Novartis, GlaxoSmithKline, for lectures from Merck, manuscript preparation from Genentech, for patents from NHLBI CARE Network, and grants from GlaxoSmithKline, Ross, Abbott. G. Wennergren has received has received fees for lectures from Novartis, Merck Sharp & Dohme, AstraZeneca and GlaxoSmithKline. J. Wildhaber has served on national and international advisory boards of Nycomed and MSD and has received research grants from AstraZeneca, GSK and MSD. R. S. Zeiger has received payment for consultancy from Aerocrine, AstraZeneca, Genentech, GlaxoSmithKline, MedImmune, ScheringPlough, Sunovion, Novartis, NHLBI/Penn State and grants from Genentech, GlaxoSmithKline, Aerocrine, Merck, MedImmune, Thermofisher. H. Arakawa, M. Mäkelä, G. Wong, H. Zar, E. Baraldi, H. P. van Bever, A. Boner, Y. Z. Chen, Y. M. El-Gamal, M. L. Everard, M. Geller, J. Gereda, D. Y. Goh, G. Hedlin, S. J. Hong, E. M. Hossny, J. L. Huang, J. C. de Jongste, N. Ait-Khaled, S. I. Lee, A. Morikawa, H. Paramesh, R. Pawankar, J. Pongracic, C. Robertson, D. Sly, S. Stick, L. M. Taussig, E. Valovirta, P. Vichyanond, D. Wallace, E. Weinberg, have no conflicts of interest to declare.

References

- Kupczyk M, Haahtela T, Cruz AA, Kuna P. Reduction of asthma burden is possible through National Asthma Plans. *Allergy* 2010;**65**:415–419.
- Lotvall J, Pawankar R, Wallace DV, Akdis CA, Rosenwasser LJ, Weber RW, et al. We call for iCAALL: International Collaboration in Asthma, Allergy and Immunology. *Allergy* 2012;**67**:449–450.
- Asthma Management Handbook. National Asthma Council Australia, Melbourne, 2006. Available from: <http://www.nationalasthma.org.au/handbook> (accessed March 2011).
- From the Global Strategy for Asthma Management and Prevention. Global Initiative for Asthma (GINA), 2011. Available from: <http://www.ginasthma.org>.
- From the Global Strategy for the Diagnosis and Management of Asthma in Children 5 Years and Younger. Global Initiative for Asthma (GINA), 2009. Available from: <http://www.ginasthma.org/>.
- Nishimuta T, Kondo N, Hamasaki Y, Morikawa A, Nishima S. Japanese guideline for childhood asthma. *Allergol Int* 2011;**60**:147–169.
- Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. *National Asthma Education and Prevention Program, Third Expert Panel on the Diagnosis and Management of Asthma*. Bethesda, MD, USA: National Heart, Lung, and Blood Institute (US), 2007.
- Bacharier LB, Boner A, Carlsen KH, Eigenmann PA, Frischer T, Gotz M, et al. Diagnosis and treatment of asthma in childhood: a PRACTALL consensus report. *Allergy* 2008;**63**:5–34.
- British Thoracic Society and Scottish Intercollegiate Guidelines Network. *British Guideline on the Management of Asthma: A National Clinical Guideline*. British Thoracic Society and Scottish Intercollegiate Guidelines Network, 2011. Available from: <http://www.sign.ac.uk/guidelines/fulltext/101/index.html>.
- Jadad AR, Moher M, Browman GP, Booker L, Sigouin C, Fuentes M, et al. Systematic reviews and meta-analyses on treatment of asthma: critical evaluation. *BMJ* 2000;**320**:537–540.
- Yunginger JW, Reed CE, O'Connell EJ, Melton LJ 3rd, O'Fallon WM, Silverstein MD. A community-based study of the epidemiology of asthma. Incidence rates, 1964–1983. *Am J Respir Crit Care Med* 1992;**146**:888–894.
- Pearce N, Ait-Khaled N, Beasley R, Mallol J, Keil U, Mitchell E, et al. Worldwide trends in the prevalence of asthma symptoms: phase III of the International Study of Asthma and Allergies in Childhood (ISAAC). *Thorax* 2007;**62**:758–766.
- Wennergren G, Ekerljung L, Alm B, Eriksson J, Lotvall J, Lundback B. Asthma in late adolescence—farm childhood is protective and the prevalence increase has levelled off. *Pediatr Allergy Immunol* 2010;**21**:806–813.
- Sackesen C, Birben E, Soyer OU, Sahiner UM, Yavuz TS, Civelek E, et al. The effect of CD14 C159T polymorphism on in vitro IgE synthesis and cytokine production by PBMC from children with asthma. *Allergy* 2011;**66**:48–57.

15. Tesse R, Pandey RC, Kabesch M. Genetic variations in toll-like receptor pathway genes influence asthma and atopy. *Allergy* 2011;**66**:307–316.
16. Tischer CG, Hohmann C, Thiering E, Herbarth O, Muller A, Henderson J, et al. Meta-analysis of mould and dampness exposure on asthma and allergy in eight European birth cohorts: an ENRIECO initiative. *Allergy* 2011;**66**:1570–1579.
17. Sporik R, Holgate ST, Platts-Mills TA, Cogswell JJ. Exposure to house-dust mite allergen (Der p I) and the development of asthma in childhood. A prospective study. *N Engl J Med* 1990;**323**:502–507.
18. Wahn U, Lau S, Bergmann R, Kulig M, Forster J, Bergmann K, et al. Indoor allergen exposure is a risk factor for sensitization during the first three years of life. *J Allergy Clin Immunol* 1997;**1**(Pt 1):763–769.
19. Chan-Yeung M, Ferguson A, Watson W, Dimich-Ward H, Rousseau R, Lilley M, et al. The Canadian Childhood Asthma Primary Prevention Study: outcomes at 7 years of age. *J Allergy Clin Immunol* 2005;**116**:49–55.
20. Woodcock A, Lowe LA, Murray CS, Simpson BM, Pipis SD, Kissen P, et al. Early life environmental control: effect on symptoms, sensitization, and lung function at age 3 years. *Am J Respir Crit Care Med* 2004;**170**:433–439.
21. Horak F Jr, Matthews S, Ihorst G, Arshad SH, Frischer T, Kuehr J, et al. Effect of mite-impermeable mattress encasings and an educational package on the development of allergies in a multinational randomized, controlled birth-cohort study – 24 months results of the Study of Prevention of Allergy in Children in Europe. *Clin Exp Allergy* 2004;**34**:1220–1225.
22. Castro-Rodriguez JA, Garcia-Marcos L, Sanchez-Solis M, Perez-Fernandez V, Martinez-Torres A, Mallol J. Olive oil during pregnancy is associated with reduced wheezing during the first year of life of the offspring. *Pediatr Pulmonol* 2010;**45**:395–402.
23. Bozzetto S, Carraro S, Giordano G, Boner A, Baraldi E. Asthma, allergy and respiratory infections: the vitamin D hypothesis. *Allergy* 2012;**67**:10–17.
24. Martinez FD. New insights into the natural history of asthma: primary prevention on the horizon. *J Allergy Clin Immunol* 2011;**128**:939–945.
25. Busse WW, Lemanske RF Jr. Asthma. *N Engl J Med* 2001;**344**:350–362.
26. Snijders D, Agostini S, Bertuola F, Panizzolo C, Baraldo S, Turato G, et al. Markers of eosinophilic and neutrophilic inflammation in bronchoalveolar lavage of asthmatic and atopic children. *Allergy* 2010;**65**:978–985.
27. Holgate ST. Epithelium dysfunction in asthma. *J Allergy Clin Immunol* 2007;**120**:1233–1244.
28. Chung KF. Airway smooth muscle cells: contributing to and regulating airway mucosal inflammation? *Eur Respir J* 2000;**15**:961–968.
29. Hamid Q, Tulic M. Immunobiology of asthma. *Annu Rev Physiol* 2009;**71**:489–507.
30. Robinson DS. The role of the mast cell in asthma: induction of airway hyperresponsiveness by interaction with smooth muscle? *J Allergy Clin Immunol* 2004;**114**:58–65.
31. Xepapadaki P, Papadopoulos NG, Bossios A, Manoussakis E, Manousakas T, Saxoni-Papageorgiou P. Duration of postviral airway hyperresponsiveness in children with asthma: effect of atopy. *J Allergy Clin Immunol* 2005;**116**:299–304.
32. Joos GF. The role of neuroeffector mechanisms in the pathogenesis of asthma. *Curr Allergy Asthma Rep* 2001;**1**:134–143.
33. Holgate ST, Polosa R. The mechanisms, diagnosis, and management of severe asthma in adults. *Lancet* 2006;**368**:780–793.
34. Fixman ED, Stewart A, Martin JG. Basic mechanisms of development of airway structural changes in asthma. *Eur Respir J* 2007;**29**:379–389.
35. Watelet JB, Van Zele T, Gjomarkaj M, Canonica GW, Dahlen SE, Fokkens W, et al. Tissue remodelling in upper airways: where is the link with lower airway remodelling? *Allergy* 2006;**61**:1249–1258.
36. Malmstrom K, Pelkonen AS, Malmberg LP, Sarna S, Lindahl H, Kajosaari M, et al. Lung function, airway remodelling and inflammation in symptomatic infants: outcome at 3 years. *Thorax* 2011;**66**:157–162.
37. Bossley CJ, Fleming L, Gupta A, Regamey N, Frith J, Oates T, et al. Pediatric severe asthma is characterized by eosinophilia and remodeling without T(H)2 cytokines. *J Allergy Clin Immunol* 2012;**129**:974–982.
38. Sears MR, Greene JM, Willan AR, Wiecek EM, Taylor DR, Flannery EM, et al. A longitudinal, population-based, cohort study of childhood asthma followed to adulthood. *N Engl J Med* 2003;**349**:1414–1422.
39. Martinez FD, Wright AL, Taussig LM, Holberg CJ, Halonen M, Morgan WJ. Asthma and wheezing in the first six years of life. The Group Health Medical Associates. *N Engl J Med* 1995;**332**:133–138.
40. Bisgaard H, Bonnelykke K. Long-term studies of the natural history of asthma in childhood. *J Allergy Clin Immunol* 2010;**126**:187–197; quiz 198–189.
41. Covar RA, Strunk R, Zeiger RS, Wilson LA, Liu AH, Weiss S, et al. Predictors of remitting, periodic, and persistent childhood asthma. *J Allergy Clin Immunol* 2010;**125**:359–366.
42. Ruotsalainen M, Piippo-Savolainen E, Hyvarinen MK, Korppi M. Adulthood asthma after wheezing in infancy: a questionnaire study at 27 years of age. *Allergy* 2010;**65**:503–509.
43. Castro-Rodriguez JA, Holberg CJ, Wright AL, Martinez FD. A clinical index to define risk of asthma in young children with recurrent wheezing. *Am J Respir Crit Care Med* 2000;**1**(Pt 1):1403–1406.
44. Leonardi NA, Spycher BD, Strippoli MP, Frey U, Silverman M, Kuehni CE. Validation of the Asthma Predictive Index and comparison with simpler clinical prediction rules. *J Allergy Clin Immunol* 2011;**127**:1466–1472.
45. Rodriguez-Martinez CE, Sossa-Briceno MP, Castro-Rodriguez JA. Discriminative properties of two predictive indices for asthma diagnosis in a sample of preschoolers with recurrent wheezing. *Pediatr Pulmonol* 2011;**46**:1175–1181.
46. Brand PL. The Asthma Predictive Index: not a useful tool in clinical practice. *J Allergy Clin Immunol* 2011;**127**:293–294.
47. Bacharier LB, Strunk RC, Mauger D, White D, Lemanske RF Jr, Sorkness CA. Classifying asthma severity in children: mismatch between symptoms, medication use, and lung function. *Am J Respir Crit Care Med* 2004;**170**:426–432.
48. Frey U. Forced oscillation technique in infants and young children. *Paediatr Respir Rev* 2005;**6**:246–254.
49. Bisgaard H, Nielsen KG. Plethysmographic measurements of specific airway resistance in young children. *Chest* 2005;**128**:355–362.
50. Schwartz LB, Delgado L, Craig T, Bonini S, Carlsen KH, Casale TB, et al. Exercise-induced hypersensitivity syndromes in recreational and competitive athletes: a PRAC-TALL consensus report (what the general practitioner should know about sports and allergy). *Allergy* 2008;**63**:953–961.
51. Cockcroft D, Davis B. Direct and indirect challenges in the clinical assessment of asthma. *Ann Allergy Asthma Immunol* 2009;**103**:363–369; quiz 369–372, 400.
52. Illi S, von Mutius E, Lau S, Niggemann B, Gruber C, Wahn U. Perennial allergen sensitisation early in life and chronic asthma in children: a birth cohort study. *Lancet* 2006;**368**:763–770.
53. Dweik RA, Boggs PB, Erzurum SC, Irvin CG, Leigh MW, Lundberg JO, et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. *Am J Respir Crit Care Med* 2011;**184**:602–615.
54. Lodrup Carlsen KC, Soderstrom L, Mowinkel P, Haland G, Pettersen M, Muntze Kaas MC, et al. Asthma prediction in school children; the value of combined

- IgE-antibodies and obstructive airways disease severity score. *Allergy* 2010;**65**:1134–1140.
55. Pedersen S. Preschool asthma—not so easy to diagnose. *Prim Care Respir J* 2007;**16**: 4–6.
 56. Brand PL, Baraldi E, Bisgaard H, Boner AL, Castro-Rodriguez JA, Custovic A, et al. Definition, assessment and treatment of wheezing disorders in preschool children: an evidence-based approach. *Eur Respir J* 2008;**32**:1096–1110.
 57. Murray CS, Woodcock A, Langley SJ, Morris J, Custovic A. Secondary prevention of asthma by the use of Inhaled Fluticasone propionate in Wheezy INfants (IFWIN): double-blind, randomised, controlled study. *Lancet* 2006;**368**:754–762.
 58. Bisgaard H, Hermansen MN, Loland L, Halkjaer LB, Buchvald F. Intermittent inhaled corticosteroids in infants with episodic wheezing. *N Engl J Med* 2006;**354**:1998–2005.
 59. Guilbert TW, Morgan WJ, Zeiger RS, Mauger DT, Boehmer SJ, Szeffler SJ, et al. Long-term inhaled corticosteroids in preschool children at high risk for asthma. *N Engl J Med* 2006;**354**:1985–1997.
 60. Vahlkvist S, Inman MD, Pedersen S. Effect of asthma treatment on fitness, daily activity and body composition in children with asthma. *Allergy* 2010;**65**:1464–1471.
 61. Durham SR, Walker SM, Varga EM, Jacobson MR, O'Brien F, Noble W, et al. Long-term clinical efficacy of grass-pollen immunotherapy. *N Engl J Med* 1999;**341**:468–475.
 62. Eng PA, Reinhold M, Gnehm HP. Long-term efficacy of preseasonal grass pollen immunotherapy in children. *Allergy* 2002;**57**:306–312.
 63. Jacobsen L, Niggemann B, Dreborg S, Ferdousi HA, Halken S, Host A, et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. *Allergy* 2007;**62**:943–948.
 64. Andrade WC, Camargos P, Lasmar L, Bousquet J. A pediatric asthma management program in a low-income setting resulting in reduced use of health service for acute asthma. *Allergy* 2010;**65**:1472–1477.
 65. Muraro A, Clark A, Beyer K, Borrego LM, Borres M, Lodrup Carlsen KC, et al. The management of the allergic child at school: EAACI/GA2LEN Task Force on the allergic child at school. *Allergy* 2010;**65**:681–689.
 66. Morgan WJ, Crain EF, Gruchalla RS, O'Connor GT, Kattan M, Evans R et al. et al. Results of a home-based environmental intervention among urban children with asthma. *N Engl J Med* 2004;**351**:1068–1080.
 67. Paramesh H. Asthma in children: seasonal variations. *Int J Environ Health* 2008;**4**:410–416.
 68. Barnes PJ. Inhaled glucocorticoids for asthma. *N Engl J Med* 1995;**332**:868–875.
 69. Zhang L, Axelsson I, Chung M, Lau J. Dose response of inhaled corticosteroids in children with persistent asthma: a systematic review. *Pediatrics* 2011;**127**:129–138.
 70. Masoli M, Weatherall M, Holt S, Beasley R. Systematic review of the dose-response relation of inhaled fluticasone propionate. *Arch Dis Child* 2004;**89**:902–907.
 71. McKean M, Ducharme F. Inhaled steroids for episodic viral wheeze of childhood. *Cochrane Database Syst Rev* 2000:CD001107.
 72. Long-term effects of budesonide or nedocromil in children with asthma. The Childhood Asthma Management Program Research Group. *N Engl J Med* 2000;**343**:1054–1063.
 73. Leone FT, Fish JE, Szeffler SJ, West SL. Systematic review of the evidence regarding potential complications of inhaled corticosteroid use in asthma: collaboration of American College of Chest Physicians, American Academy of Allergy, Asthma, and Immunology, and American College of Allergy, Asthma, and Immunology. *Chest* 2003;**124**:2329–2340.
 74. Guilbert TW, Mauger DT, Allen DB, Zeiger RS, Lemanske RF Jr, Szeffler SJ, et al. Growth of preschool children at high risk for asthma 2 years after discontinuation of fluticasone. *J Allergy Clin Immunol* 2011;**128**:956–963.
 75. Strunk RC, Sternberg AL, Szeffler SJ, Zeiger RS, Bender B, Tonascia J. Long-term budesonide or nedocromil treatment, once discontinued, does not alter the course of mild to moderate asthma in children and adolescents. *J Pediatr* 2009;**154**:682–687.
 76. Lipworth BJ. Leukotriene-receptor antagonists. *Lancet* 1999;**353**:57–62.
 77. Drazen JM, Israel E, O'Byrne PM. Treatment of asthma with drugs modifying the leukotriene pathway. *N Engl J Med* 1999;**340**:197–206.
 78. Price D, Musgrave SD, Shepstone L, Hillier EV, Sims EJ, Gilbert RF, et al. Leukotriene antagonists as first-line or add-on asthma-controller therapy. *N Engl J Med* 2011;**364**:1695–1707.
 79. Garcia Garcia ML, Wahn U, Gilles L, Swern A, Tozzi CA, Polos P. Montelukast, compared with fluticasone, for control of asthma among 6- to 14-year-old patients with mild asthma: the MOSAIC study. *Pediatrics* 2005;**116**:360–369.
 80. Stelmach I, Grzelewski T, Majak P, Jerzynska J, Stelmach W, Kuna P. Effect of different antiasthmatic treatments on exercise-induced bronchoconstriction in children with asthma. *J Allergy Clin Immunol* 2008;**121**:383–389.
 81. Ram FS, Cates CJ, Ducharme FM. Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma. *Cochrane Database Syst Rev* 2005: CD003137.
 82. Woolcock A, Lundback B, Ringdal N, Jacques LA. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. *Am J Respir Crit Care Med* 1996;**153**:1481–1488.
 83. Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group. *Lancet* 1994;**344**:219–224.
 84. Ducharme FM, Ni Chroinin M, Greenstone I, Lasserson TJ. Addition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma. *Cochrane Database Syst Rev* 2010:CD005533.
 85. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM. The Salmeterol Multi-center Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. *Chest* 2006;**129**:15–26.
 86. McMahon AW, Levenson MS, McEvoy BW, Mosholder AD, Murphy D. Age and risks of FDA-approved long-acting beta-adrenergic receptor agonists. *Pediatrics* 2011;**128**:e1147–e1154.
 87. Rodrigo GJ, Castro-Rodriguez JA. Safety of long-acting beta agonists for the treatment of asthma: clearing the air. *Thorax* 2012;**67**:342–349.
 88. Main C, Shepherd J, Anderson R, Rogers G, Thompson-Coon J, Liu Z, et al. Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in children under the age of 12 years. *Health Technol Assess* 2008;**12**:1–174, iii–iv.
 89. Ducharme FM, Ni Chroinin M, Greenstone I, Lasserson TJ. Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children. *Cochrane Database Syst Rev* 2010: CD005535.
 90. Lemanske RF Jr, Mauger DT, Sorkness CA, Jackson DJ, Boehmer SJ, Martinez FD, et al. Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. *N Engl J Med* 2010;**362**:975–985.

91. Sears MR. Safety of long-acting beta-agonists: are new data really required? *Chest* 2009;**136**:604–607.
92. Lemanske RF Jr, Busse WW. The US Food and Drug Administration and long-acting beta₂-agonists: the importance of striking the right balance between risks and benefits of therapy? *J Allergy Clin Immunol* 2010;**126**:449–452.
93. Bisgaard H, Le Roux P, Bjamer D, Dymek A, Vermeulen JH, Hultquist C. Budesonide/formoterol maintenance plus reliever therapy: a new strategy in pediatric asthma. *Chest* 2006;**130**:1733–1743.
94. Edwards AM, Stevens MT. The clinical efficacy of inhaled nedocromil sodium (Tilade) in the treatment of asthma. *Eur Respir J* 1993;**6**:35–41.
95. Szefer SJ, Nelson HS. Alternative agents for anti-inflammatory treatment of asthma. *J Allergy Clin Immunol* 1998;**2**(Pt 2):S23–S35.
96. Weinberger M, Hendeles L. Theophylline in asthma. *N Engl J Med* 1996;**334**:1380–1388.
97. Walker S, Monteil M, Phelan K, Lasserson TJ, Walters EH. Anti-IgE for chronic asthma in adults and children. *Cochrane Database Syst Rev* 2006:CD003559.
98. Finn A, Gross G, van Bavel J, Lee T, Windom H, Everhard F, et al. Omalizumab improves asthma-related quality of life in patients with severe allergic asthma. *J Allergy Clin Immunol* 2003;**111**:278–284.
99. Rodrigo GJ, Neffen H, Castro-Rodriguez JA. Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review. *Chest* 2011;**139**:28–35.
100. Kopp MV. Role of immunomodulators in allergen-specific immunotherapy. *Allergy* 2011;**66**:792–797.
101. Bleecker ER, Welch MJ, Weinstein SF, Kalberg C, Johnson M, Edwards L, et al. Low-dose inhaled fluticasone propionate versus oral zafirlukast in the treatment of persistent asthma. *J Allergy Clin Immunol* 2000;**1**(Pt 1):1123–1129.
102. Busse W, Raphael GD, Galant S, Kalberg C, Goode-Sellers S, Srebro S, et al. Low-dose fluticasone propionate compared with montelukast for first-line treatment of persistent asthma: a randomized clinical trial. *J Allergy Clin Immunol* 2001;**107**:461–468.
103. Szefer SJ, Phillips BR, Martinez FD, Chinchilli VM, Lemanske RF, Strunk RC, et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. *J Allergy Clin Immunol* 2005;**115**:233–242.
104. Bisgaard H, Skoner D, Boza ML, Tozzi CA, Newcomb K, Reiss TF, et al. Safety and tolerability of montelukast in placebo-controlled pediatric studies and their open-label extensions. *Pediatr Pulmonol* 2009;**44**:568–579.
105. Ballardini N, Kull I, Lind T, Hallner E, Almqvist C, Ostblom E, et al. Development and comorbidity of eczema, asthma and rhinitis to age 12: data from the BAMSE birth cohort. *Allergy* 2012;**67**:537–544.
106. Ait-Khaled N, Enarson DA, Chiang C-Y, Marks G, Bissell K. *Management of Asthma: A Guide to Essentials of Good Practice*. Paris, France: International Union Against Tuberculosis and Lung Disease, 2008.
107. Dolovich MB, Ahrens RC, Hess DR, Anderson P, Dhand R, Rau JL, et al. Device selection and outcomes of aerosol therapy: evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. *Chest* 2005;**127**:335–371.
108. Laube BL, Janssens HM, de Jongh FH, Devadason SG, Dhand R, Diot P, et al. What the pulmonary specialist should know about the new inhalation therapies. *Eur Respir J* 2011;**37**:1308–1331.
109. De Benedictis FM, Selvaggio D. Use of inhaler devices in pediatric asthma. *Paediatr Drugs* 2003;**5**:629–638.
110. Castro-Rodriguez JA, Rodrigo GJ. beta-agonists through metered-dose inhaler with valved holding chamber versus nebulizer for acute exacerbation of wheezing or asthma in children under 5 years of age: a systematic review with meta-analysis. *J Pediatr* 2004;**145**:172–177.
111. Cates CJ, Crilly JA, Rowe BH. Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma. *Cochrane Database Syst Rev* 2006:CD000052.
112. Pierart F, Wildhaber JH, Vrancken I, Devadason SG, Le Souef PN. Washing plastic spacers in household detergent reduces electrostatic charge and greatly improves delivery. *Eur Respir J* 1999;**13**:673–678.
113. Zar HJ, Brown G, Donson H, Brathwaite N, Mann MD, Weinberg EG. Home-made spacers for bronchodilator therapy in children with acute asthma: a randomised trial. *Lancet* 1999;**354**:979–982.
114. Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. *J Allergy Clin Immunol* 1998;**1**(Pt 1):558–562.
115. Calderon MA, Cox L, Casale TB, Moinjeon P, Demoly P. Multiple-allergen and single-allergen immunotherapy strategies in polysensitized patients: looking at the published evidence. *J Allergy Clin Immunol* 2012;**129**:929–934.
116. European Academy of Allergy and Clinical Immunology. *European Declaration on Allergen Immunotherapy*. European Academy of Allergy and Clinical Immunology, 2011. Available from: eaaci.net.
117. Pajno GB, Barberio G, De Luca F, Morabito L, Parmiani S. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. *Clin Exp Allergy* 2001;**31**:1392–1397.
118. Bernstein DI, Wanner M, Borish L, Liss GM. Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990–2001. *J Allergy Clin Immunol* 2004;**113**:1129–1136.
119. Penagos M, Passalacqua G, Compalati E, Baena-Cagnani CE, Orozco S, Pedroza A, et al. Metaanalysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age. *Chest* 2008;**133**:599–609.
120. Nathan RA, Sorkness CA, Kosinski M, Schatz M, Li JT, Marcus P, et al. Development of the asthma control test: a survey for assessing asthma control. *J Allergy Clin Immunol* 2004;**113**:59–65.
121. Juniper EF, O'Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. *Eur Respir J* 1999;**14**:902–907.
122. Liu AH, Zeiger R, Sorkness C, Mahr T, Ostrom N, Burgess S, et al. Development and cross-sectional validation of the Childhood Asthma Control Test. *J Allergy Clin Immunol* 2007;**119**:817–825.
123. Murphy KR, Zeiger RS, Kosinski M, Chipps B, Mellon M, Schatz M, et al. Test for respiratory and asthma control in kids (TRACK): a caregiver-completed questionnaire for preschool-aged children. *J Allergy Clin Immunol* 2009;**123**:833–839.
124. Wildfire JJ, Gergen PJ, Sorkness CA, Mitchell HE, Calatroni A, Kattan M, et al. Development and validation of the Composite Asthma Severity Index—an outcome measure for use in children and adolescents. *J Allergy Clin Immunol* 2012;**129**:694–701.
125. Gibson NA, Ferguson AE, Aitchison TC, Paton JY. Compliance with inhaled asthma medication in preschool children. *Thorax* 1995;**50**:1274–1279.
126. Minai BA, Martin JE, Cohn RC. Results of a physician and respiratory therapist collaborative effort to improve long-term metered-dose inhaler technique in a pediatric asthma clinic. *Respir Care* 2004;**49**:600–605.
127. van der Valk RJ, Baraldi E, Stern G, Frey U, de Jongste JC. Daily exhaled nitric

- oxide measurements and asthma exacerbations in children. *Allergy* 2012;**67**:265–271.
128. Smith AD, Cowan JO, Brassett KP, Herbi-son GP, Taylor DR. Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. *N Engl J Med* 2005;**352**:2163–2173.
129. Petsky HL, Cates CJ, Li A, Kynaston JA, Turner C, Chang AB. Tailored interven-tions based on exhaled nitric oxide versus clinical symptoms for asthma in children and adults. *Cochrane Database Syst Rev* 2009;CD006340.
130. Nuijsink M, Hop WC, Sterk PJ, Duiver-man EJ, de Jongste JC. Long-term asthma treatment guided by airway hyperrespon-siveness in children: a randomised controlled trial. *Eur Respir J* 2007;**30**:457–466.
131. Sont JK, Willems LN, Bel EH, Van Krieken JH, Vandenbroucke JP, Sterk PJ. Clinical control and histopathologic outcome of asthma when using airway hyperresponsive-ness as an additional guide to long-term treatment. The AMPUL Study Group. *Am J Respir Crit Care Med* 1999;**1**(Pt 1):1043–1051.
132. Jackson DJ, Sykes A, Mallia P, Johnston SL. Asthma exacerbations: origin, effect, and prevention. *J Allergy Clin Immunol* 2011;**128**:1165–1174.
133. Papadopoulos NG, Christodoulou I, Rohde G, Agache I, Almqvist C, Bruno A, et al. Viruses and bacteria in acute asthma exac-erbations—a GA(2) LEN-DARE systematic review. *Allergy* 2011;**66**:458–468.
134. Taylor DR, Bateman ED, Boulet LP, Bou-shey HA, Busse WW, Casale TB, et al. A new perspective on concepts of asthma severity and control. *Eur Respir J* 2008;**32**:545–554.
135. FitzGerald JM, Shragge D, Haddon J, Jen-nings B, Lee J, Bai T, et al. A randomized, controlled trial of high dose, inhaled budes-onide versus oral prednisone in patients dis-charged from the emergency department following an acute asthma exacerbation. *Can Respir J* 2000;**7**:61–67.
136. Ducharme FM, Lemire C, Noya FJ, Davis GM, Alos N, Leblond H, et al. Preemptive use of high-dose fluticasone for virus-induced wheezing in young children. *N Engl J Med* 2009;**360**:339–353.
137. Robertson CF, Price D, Henry R, Mellis C, Glasgow N, Fitzgerald D, et al. Short-course montelukast for intermittent asthma in children: a randomized controlled trial. *Am J Respir Crit Care Med* 2007;**175**:323–329.
138. Rabe KF, Vermeire PA, Soriano JB, Maier WC. Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study. *Eur Respir J* 2000;**16**:802–807.
139. Szefer SJ. Advancing asthma care: the glass is only half full! *J Allergy Clin Immunol* 2011;**128**:485–494.